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1. Introduction 
 
1.1 Chronic Kidney Disease 
Chronic Kidney Disease (CKD) is a gradual and progressive loss of kidney 
function that often leads to End Stage Renal Disease (ESRD). The loss of renal function 
usually takes many years to occur and there may be no symptoms at early stages of the 
disease1. In fact, progression may be so gradual that symptoms do not occur until 
kidney function is less than one-tenth of normal. ESRD is the most advanced form of 
CKD which requires kidney replacement to ensure survival2.  
The development and progression to CKD involves many complications and 
consequences that finally lead to ESRD. Kidney Disease Improving Global Outcomes 
(KDIGO) conceptual model describes the various stages, risk factors and complications 
associated with the progression of CKD to kidney failure and death1 (Figure 1). KDIGO 
defined CKD as abnormalities of kidney structure or function present for 3 months or 
longer. The CKD is classified into different stages based on the decline in the 
glomerular filtration rate (GFR) and the severity of albuminuria3 (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Conceptual model of chronic kidney disease. This diagram presents the continuum of 
development, progression, and complications of chronic kidney disease. Green circles represent stages of 
chronic kidney disease, aqua circles represent potential antecedents, lavender circles represent 
consequences, and thick arrows between ellipses represent risk factors associated with the development, 
progression, and remission of chronic kidney disease. ‘Complications’ refers to all complications of 
chronic kidney disease and interventions for its treatment and prevention, including complications of 
decreased glomerular filtration rate and cardiovascular disease. Adapted from A.S.Levey et. al.3 
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Table 1: Prognosis of chronic kidney disease: The revised classification of Chronic Kidney Disease 
by KDIGO. Adapted from KDIGO, Kidney International, 2013 
 
 
  
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The colours represent the intensities of risk. Green: low risk (if no other markers of kidney disease, no 
CKD); Yellow: moderately increased risk; Orange: high risk; Red: very high risk 
Abbreviations: GFR, glomerular filtration rate 
 
 
Though the abnormalities of kidney damage generally ascertained from albuminuria, 
other objective measures (urine sediment, pathology or imaging studies, acid-base and 
electrolyte disorders due to tubular disorders, or history of kidney transplantation) also 
help in assessing the disease (KDIGO Kidney International 2013).  
The prevalence of CKD continues to increase worldwide and approximately 600 
million people are affected worldwide.  For example, CKD affects about 14 to 15% of 
the adult US population and is projected to increase by 50% in the next 20 years4. 
Diabetes, obesity and hypertension are the most common causes that account for 
approximately two thirds of the cases of chronic renal failure and ESRD3. Other diseases 
and conditions such as autoimmune and hereditary disorders5,6, infections7,8 (HBV, 
HCV and HIV) and diabetic nephropathy (DN)9,10 have shown to be associated with the 
development and progression of CKD. Among these, DN is one of the major causes of 
CKD9. 
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1.2 Diabetic Nephropathy 
 
Diabetes Mellitus 
Diabetes Mellitus (DM) is characterized by hyperglycaemia with disturbances in 
carbohydrate, protein and fat metabolism caused by complete or relative insufficiency 
of insulin secretion and/or insulin action11. 
There are mainly two forms of diabetes mellitus, insulin-dependent diabetes 
mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM). IDDM or type 
1 diabetes (T1D) is characterized by a progressive destruction of the insulin-producing 
β-cells in the pancreas, usually due to auto-immune response, which leads to insulin 
deficiency. In addition to that, various genetic and environmental factors, for example, 
exposure to viruses also contribute to T1D which accounts for about 10-15% of all 
people with DM12. 
Non-insulin-dependent or adult-onset diabetes mellitus or type 2 diabetes (T2D) 
is characterized by insulin resistance or relative insulin deficiency. This is the most 
common form of diabetes and accounts for almost 90-95% of all cases of diabetes in 
adults worldwide. The incidence of T2D is mainly due to lifestyle changes, such as 
high-fat diet and physical inactivity and yet, several genetic epidemiological studies 
demonstrate that both obesity and T2D are highly inherited traits13. There are other 
forms of DM namely, maturity onset diabetes of the young (MODY) and gestational 
diabetes (GD) occurring with relatively low prevalence. 
 
Prevalence of Diabetes 
The worldwide prevalence of diabetes for all age groups is estimated to be 2.8%; 
of which 8.3%  are reported to be adults between 20-79 age in year 201114. According 
to International Diabetes Federation (IDF), the total number of people living with 
diabetes across the world is around 366 million and expected to hit 552 million by the 
year 2030 and it is equal to 3 new cases every 10 second or 10 million per year. In 
general, on an average, nearly 8% of adults living in highly developed countries have 
diabetes14. According to ‘London School of Economics (LSE) diabetes report’ 2012, 
diabetes prevalence in European population has been increasing over the past two 
decades and it has estimated that among all European countries, Germany has the 
highest diabetes prevalence rate of 8.9% and approximately 6 people per every hour die 
from diabetes and complications associated with it15. Today, it is estimated that one in 
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every 13 persons in Germany has diabetes. The IDF estimates that by 2030 the number 
of people with diabetes will increase to 8 million, which corresponds to 13.5% of total 
diabetic population (www.dzd-ev.de). 
 
Diabetes and its complications 
Uncontrolled and prolonged hyperglycaemia in diabetic patients often leads to 
several macro and micro vascular complications. Major microvascular complications 
include retinal abnormalities (diabetic retinopathy), autonomic, sensory, and motor 
neuropathies (diabetic neuropathy) and renal impairment (DN). 
 
Diabetic nephropathy 
DN is the leading cause of CKD in the Western world, and is one of the most 
significant long-term complications leading to increased morbidity and mortality in 
patients with T2D16. Approximately 25-30% of patients with T1D or T2D will develop 
overt DN, where half of all patients will require hemodialysis treatment17. DN is 
characterized by hypertension, progressive albuminuria, glomerulosclerosis, and decline 
in GFR, leading to ESRD. Based on the decline in the GFR and albuminuria, DN is 
classified into 5 stages18 (Table 2). 
In DN, the glomerular tuft undergoes a slow but progressive structural 
remodelling characterized by glomerular hypertrophy, accumulation of extracellular 
mesangial matrix, and podocyte damage19 (Figure 2). The latter have been shown to 
account for the progression of micro-albuminuria from early stages to overt proteinuria. 
These changes eventually lead to glomerular sclerosis at late stage DN which 
progressively destroys the renal function and finally leads to kidney failure. The 
development and progression of DN to ESRD involves multiple pathomechanisms 
(Figure 3) that finally contribute to the scaring of glomerulus, known as 
glomerulosclerosis which is manifested by either nodular or diffuse lesions 
(www.emedline.com).  
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Table 2: KDOQI classification of different stages associated with various stages of DN. 
 
Stage Description Characteristic features 
 
GFR* 
 
 
Prevalence 
% 
 
1 
 
 
 
2 
 
 
3 
 
 
4 
 
5 
 
Kidney damage with 
normal or slight 
increase in GFR 
 
Kidney damage with 
mildly reduced GFR 
 
Moderately impaired 
GFR 
 
Severe impaired GFR 
 
Kidney failure 
 
Glomerular  
hyperfiltration 
 
 
Thickened GBM, 
expanded mesangium 
 
Microalbuminuria 
 
 
Macroalbuminuria 
 
ESRD 
 
>90 
 
 
 
60-90 
 
 
30-59 
 
 
15-29 
 
<15 or  
 dialysis 
 
3.3 
 
 
 
3 
 
 
4.3 
 
 
0.2 
 
 
0.2 
 
Adapted and modified from Levey et. al18. 
*mL/min/1.73 m2 
Abbreviations:  GFR, glomerular filtration rate;  
   GBM, glomerular basement membrane;  
   ESRD, end stage renal disease; 
   KDOQI, Kidney Disease Outcomes Quality Initiative 
 
 
 
 
 
 
 
 
 
 
Figure 2: Periodic acid–Schiff stain of glomeruli. (A) Normal glomerular with wide open capillaries 
and normal vasculature. (B) Mesangial matrix accumulation, thickened GBM and collapsed capillaries 
(Obtained from http://drugline.org). 
 
 
 
 
A  
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Figure 3: Overview of multiple pathomechanisms involved in the progression of DN. Adapted from 
J.F Navarro et al.20 
 
 
1.2.1 Pathophysiology of diabetic nephropathy 
 
Glomerulosclerosis 
 
Glomerulosclerosis is a major cause of DN. The development and progression of 
DN to glomerulosclerosis involves all cell types (mesangial cells, endothelial cells and 
podocytes) in the glomerular tuft. Recent studies report that both the glomerulus and the 
tubulointerstitium are involved in the pathophysiologic changes contributing to 
progression of the disease19. Though mesangial cells are in front in the development and 
progression of the disease, the cross talk between all cell types plays an important role 
in the evolution of diabetic glomerulosclerosis. However, the loss of podocytes, the 
glomerular epithelial cell that represents the main constituent of the glomerular filtration 
barrier (GFB), is the crucial driver of progression towards glomerulosclerosis21,22. A 
number of factors, including genetic, mechanical, and immunological stresses, as well 
as toxins, can cause podocyte injury23-26.  
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Podocytes loss 
 
The GFB is a highly specialized blood filtration unit consisting of three major 
components: the fenestrated endothelial cell, the glomerular basement membrane 
(GBM), and the visceral epithelial cells, called podocytes. Podocytes are highly 
specialized epithelial cells of mesenchymal origin located on the urinary aspect of the 
GFB27,28. Growing evidences suggest that loss of podocytes plays a key role in the 
progression towards glomerulosclerosis. For example, reduction in the number of 
podocytes is proportional to the extent of albuminuria in many diseases including DN29-
31
, focal segmental glomerulosclerosis (FSGS) and IgA nephropathy29,32. Various 
insults, including genetic, mechanical, and immunological stress, as well as toxins, alter 
the structural and functional cytoskeleton of the podocytes and its slit diaphragm33-35. 
Since these podocytes are terminally differentiated and cannot undergo cell division, 
any repair/proliferative response of surviving podocytes often lead to podocyte 
detachment from the GBM either as a consequence of sublethal injury or from apoptotic 
or necrotic death36,37, now referred to as “mitotic catastrophe”38,39. Mitotic catastrophe is 
defined as “cell death during mitosis” by an incomplete assembly of the chromosomes 
and the mitotic spindle in the pro-metaphase which then leads to aberrant chromosome 
segregation40. Such cells die either immediately within mitosis or shortly after via 
apoptosis or necrosis. Morphologic features of mitotic catastrophe include multiple 
nuclei, micronuclei or irregularly shaped nuclei36,41,42. In vitro studies suggest that 
cultured podocytes lack the ability to reproduce the in vivo podocyte cytoskeletal 
phenotype43. In addition, several experimental models have addressed that either 
podocyte depletion or podocyte injury is sufficient to induce glomerulosclerosis and the 
degree of podocyte depletion positively correlates with the severity of the 
glomerulosclerosis44,45. Furthermore, it has been show that replacement of podocytes 
(either recovery or repair) contributes to the regression of glomerulosclerosis44,46-48. 
However, a large body of evidence over the past decade suggest the involvement of 
many inflammatory pathways that finally leads to podocyte loss and glomerulosclerosis 
in DN20. 
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1.2.2 The role of inflammation in the pathophysiology of diabetic nephropathy 
As depicted in figure 3, all components of diabetic milieu (high glucose, 
hemodynamic changes, metabolic abnormalities, advanced glycation end products 
(AGEs), and oxidative stress act on all types of kidney cells (endothelial, mesangial, 
epithelial, tubular cells, and podocytes) and activate diverse molecular signal cascades. 
Activation of these signalling pathways result in infiltration of circulating inflammatory 
cells, which amplifies and perpetuates the inflammatory process in the kidney to 
produce various cytokine and chemokines, finally resulting in development and 
progression of DN. Many studies have shown that chronic inflammation is associated 
with the progression of kidney disease in T2D, implying the role of inflammatory 
processes in the disease progression49. 
 
Recruitment of inflammatory cells 
 
There are increasing evidences suggesting the involvement of immune cells in 
the DN50,51. The chemokines produced by elements of diabetic milieu direct the 
migration of leukocytes into kidney and promote further inflammation52,53. The steps 
involved in the recruitment of leukocytes into kidney are discussed in detail in 
“chemokines and chemotaxis” section. 
 
Macrophages 
 
Macrophages are one of the central mediators of renal vascular inflammation in 
diabetes mellitus, and promote DN54. It has been shown in renal biopsies of human DN, 
macrophages accumulate in the glomeruli and interstitium even in the early stages of the 
disease. Recent studies also demonstrate that macrophage-derived products can induce 
further inflammation in the diabetic kidney. After infiltration into tissues, these 
macrophages produce various cytokines, reactive oxygen species (ROS), profibrotic and 
anti-angiogenic factors which are crucial mediators of renal damage. In different 
experimental models of DN, renal macrophage accumulation correlates with increased 
chemokine production, glomerular and tubule-interstitial injury, and progressive 
fibrosis. Adoptive transfer studies in a mouse model of experimental glomerulonephritis 
showed that macrophages can induce proteinuria and mesangial proliferation55. 
Together, macrophages and their products exacerbate inflammation in the kidneys of 
patients with DM implicating their pathological role in DN.   
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Macrophages recruitment 
 
Research during the past decade demonstrated that diabetic patients with 
nephropathy have elevated plasma levels of ICAM-1(intercellular adhesion molecule-
1)56. ICAM-1 on vascular endothelium actively controls the homing of macrophages 
into the kidney. ICAM-1 serves as a ligand for LFA-1 on monocytes, facilitating 
leukocyte adhesion and transmigration. It has been demonstrated that various factors 
such as hyperglycemia57, AGEs58, oxidative stress59, and hyper-insulinemia can induce 
ICAM-1 expression in kidneys of both type 1 and type 2 diabetic mice. ICAM-1 
deficient db/db mice showed significant reduction in albuminuria, glomerular and 
tubulointerstitial injury and associated with reduction in the number of glomerular and 
interstitial macrophages60. In addition, in experimental DN, blockade of c-fms, the 
receptor for colony stimulating factor-1,  and the major cytokine known to promote 
local macrophage proliferation, prevented the progression and development of the 
disease61,62. 
 
1.3 Chemokines and chemokine receptors 
 
1.3.1 Chemokines 
Chemokines constitute a large family of small, secreted and structurally related 
proteins that are mainly involved in leukocyte attraction63. Like cytokines, chemokines 
have other activities, including regulation of angiogenesis, fibrosis, proliferation, and 
apoptosis64-66. Almost all cell types have the ability to produce these proteins whose 
molecular weight is in the range between 8 and 10 kDa. To date, approximately 50 
chemokines have been discovered66 (Table 3). 
Chemokines are classified on the basis of number and position of the first two 
conserved N-terminal cysteine residues, CXC and CC, depending on whether they have 
an intervening amino acid (X) between them (CXC) or are adjacent (CC)67,68. In 
addition, two other classes of chemokines have been described: lymphotactin (C or 
SCYc) and fractalkine (CX3C or SCYd). The former one lacks an N-terminal cysteine, 
while the latter exhibit three amino acids between the first two cysteines and is also the 
only membrane-bound chemokine attached via a mucin like stalk69. In 2000, a 
nomenclature system was introduced to describe the chemokines based on the ligand 
(L), their receptors (R) and subgroups they belong to68,70,71. Some CXC chemokines are 
further classified by the presence of three amino acid motif ‘E-L-R’ (glutamic acid-
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leucine-arginine) at N-terminal of the first conserved cysteine residue. These E-L-R-
CXC chemokines are the potential neutrophil chemo attractants. In contrast, the CXC 
chemokines that lack the E-L-R motif bind different CXC receptors on lymphocytes and 
inhibit angiogenesis64,72. 
In addition, chemokines are further divided according to their function, homeostatic and 
inflammatory chemokines (Table 3). Inflammatory chemokines or inducible cytokines 
are produced in response to acute and chronic inflammatory processes, while 
homeostatic chemokines are produced constitutively and usually control the 
homeostatic trafficking of leukocytes under steady state conditions and have so-called 
"housekeeping" functions, like homing and migration, haematopoiesis, immune 
surveillance, and adaptive immune responses67,70,73. For example, consistent expression 
of CCL17/TARC and CCL19/MIP-3β at high levels in thymus and lymph nodes are 
responsible for physiological migration of T and B lymphocytes into the lymphoid 
organs74,75. However, some chemokines fall into both categories depending on the 
biological context or pathological state, called “dual function chemokines”76. These 
chemokines are involved in adaptive immunity, T- lymphopoiesis, trafficking of T and 
B cell in small intestine, dendritic cell development, and homing to particular anatomic 
compartments77,78. 
 
1.3.2 Chemokine receptors 
Interaction with specific receptors is a crucial determinant of the chemokines 
spectrum. Chemokine receptors belong to the G-protein-coupled receptor (GPCR) 
serpentine super family and contain extra, intra and cytoplasmic domains79,80. As with 
any G-protein-mediated activation cascade, the external interface contributes to the 
specificity of ligand recognition, which triggers the exchange of GDP for GTP on the α-
Subunit of the G-protein. This G-protein, then dissociates from the receptor and binds to 
the effector molecules which then activate the signaling cascade in the cytoplasmic loop 
of the effector cell. This process ultimately leads to cell mobilization and activation80,81. 
In addition, chemokine receptors with structural features that are inconsistent with a 
signalling function have also been described. These receptors are called “silent or non-
signalling receptors” which do not signal via the typical G-protein-mediated pathways, 
but regulate inflammatory and immune reactions in several ways, including by acting as 
decoy receptors and scavenger receptors66,82,83. To date, more than 20 chemokine 
receptors have been molecularly defined (Table 3). 
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Table 3: List of chemokines and chemokine receptors 
 
Nomenclature            Old name               Receptor 
 
Proinflammatory chemokines 
 
CC family 
CCL1     I-309                    CCR8 
CCL2     CCL2                   CCR2   
CCL3     MIP1αS                 CCR1, CCR4 
CCL3L1     MIP1αP                 CCR1, CCR5 
CCL4     MIP1β                  CCR5  
CCL5     RANTES                CCR1, CCR3, CCR5 
CCL7     MCP3                   CCR1, CCR2, CCR3 
CCL8     MCP2                   CCR2, CCR5 
CCL11     Eotaxin                  CCR3 
CCL13     MCP4                   CCR1, CCR2 
CCL23     MPIF-1                  CCR1 
CCL24     Eotaxin-2                CCR3 
CCL26     Eotaxin-3                CCR3 
CCL28     MEC                    CCR10 
CXC family 
CXCL1     GRO-α                  CXCR2 
CXCL2     GRO-β                  CXCR2 
CXCL3     GRO-γ                  CXCR2 
CXCL5     ENA-78                 CXCR2 
CXCL6     GCP-2                  CXCR1, CXCR2 
CXCL7     NAP-2                  CXCR1, CXCR2 
CXCL8     IL-8                     CXCR1, CXCR2 
CXCL9     MIG                    CXCR3A, CXCR3B 
CXCL10     IP-10                    CXCR3A, CXCR3B 
CXCL11     ITAC                   CXCR3A, CXCR3B,  CXCR7 
CXCL14     BRAK , BMAC, MIP-2γ   Unknown 
CXCL16                             CXCR6 
CX3CL1     Fractalkine               CX3CR1 
 
Mixed function chemokine and receptors 
CC family 
CCL17     TARC                   CCR4 
CCL20     MIP3α                  CCR6 
CCL21     SLC                    CCR7 
CCL22     MDC                   CCR4 
X-C family 
XCL1     Lymphotactin            XCR1 
XCL2     SCM1β                  XCR1 
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Nomenclature            Old name               Receptor 
Homeostatic chemokine and receptors 
CC family 
CCL14      HCC-1                  CCR1 
CCL15      HCC-2                  CCR1, CCR3 
CCL16      HCC-4                  CCR1, CCR3 
CCL18      PARC                   PITPNM3  
(Jingqi Chen et. al. 2011) 
CCL19      ELC                    CCR7  
CCL25      TECK                   CCR9 
CCL27      CTACK                 CCR10 
CXC family 
CXCL4      PF4                     CXCR3B 
CXCL12      CXCL12α/β              CXCR4, CXCR7 
CXCL13      BCA-1                  CXCR5 
 
Silent chemokine receptors 
Receptor      Ligand 
CCX CKR     CCL19, 21, 25 
DARC        CCL1, 2, 5, 7, 8, 11, 13, 14, 16, 17, 18 
CXCL1, 35, 6, 8 
D6            CCL2, 3, 4, 5, 7, 8, 11, 12, 13, 14, 17, 22, 23, 24 
CCRL2        CCL19 
 
Chemokines and chemotaxis 
The immune system has adapted to respond to any foreign antigen and/or tissue 
damage, and other physiological insults84. This ability is greatly depending on 
chemokine networks to recruit specific leukocytes to the right place by process called, 
chemotaxis, which involves three steps: rolling, adhesion and transmigration85,86 (Figure 
4). 
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Figure 4: The mechanism of chemotaxis. Adapted from J.F. Navarro et. al. 201120 
 
E-selectin, ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1) are cell 
adhesion molecules that actively control the transmigration of leukocytes into renal 
tissue via the adhesion cascade87. First step is "rolling" of leukocytes through the 
capillary endothelium. This transient process involves the selectins on the endothelium 
which interact with mucin receptors on the leukocytes via labile interactions causing a 
rolling behaviour of the leukocyte along the cell surface and this allows the firm 
adhesion of leukocytes to the endothelium86,88. Chemokines secreted in response to pro-
inflammatory signals, are thought to bind GAGs on endothelial cell surface as a 
mechanism for retention at the inflammatory site89. This adhesion is an irreversible 
process required for the subsequent trans-endothelial extravagation of the cells from the 
blood into tissue along chemokine gradients90,91. This process is called “haptotaxis”92. 
Once the activated leukocyte reaches the site of tissue damage, it produces more 
effective chemokines and cytokines locally and thus exacerbates tissue damage76. 
 
Function of chemokines 
In addition to chemotaxis, chemokines have other effects including, changes in 
cell shape, extension of lamellipodia through cytoskeletal restructuring, release of 
oxygen radicals, and cytotoxic proteins from neutrophils, basophils, and eosinophils. 
Besides these pro-inflammatory effects, chemokines have also attributed to other 
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growth promoting functions. For example, the CXC family chemokines are identified as 
growth factors93,94. The chemokine growth-related oncogene-α (GRO-α) was originally 
identified as an autocrine growth factor for melanoma cells95. IL-8 and epithelial cell-
derived neutrophil attractant-78 (ENA-78) have shown to be angiogenic96,97, while 
platelet factor-4 (PF-4), interferon (IFN)-inducible protein (IP-10) , monokine induced 
by interferon-γ (MIG), stromal cell-derived factor-1 (SDF-1), and IFN-inducible T-cell 
alpha chemoattractant (I-TAC)/CXCL11 act as angiostatic factors98-101. Chemokine 
RANTES (regulated upon activation, normal T cell expressed and secreted) can induce 
eosinophil and basophil degranulation102. To summarize, the expression of chemokines 
helps in determining the micro-vascularization within the tissue during embryogenesis, 
wound healing, tumor growth and chronic inflammation. 
 
1.3.3 Role of chemokines and chemokine receptors in chronic kidney disease 
Chemo-attraction is an essential component of the host defence mechanism to 
attract leukocytes to sites of inflammation and infection103. Chemokines and chemokine 
receptors are an integral part of this process and have been implicated in the 
pathophysiology of many infectious and inflammatory diseases104. Since inflammation 
is often a double-edged sword, this robust protective response can sometimes be 
deleterious in many inflammatory diseases characterized by recruitment of 
inflammatory cells into tissues including DN, resulting in organ dysfunction20,62. Since 
MCP-1 (monocyte chemo-attractant protein-1) or CCL2 and CXCL12 are amongst the 
chemokines of interest, I would like to elaborately discuss these molecules and their 
role in DN.  
 
1.3.4 CCL2/MCP-1 
CCL2 is the first discovered and most extensively studied chemokine105. It 
belongs to CC-class chemokine family that exhibits its most potent chemo-tactic 
activity towards monocytes-macrophage (M/MØ) lineage and promotes their 
transmigration into various tissues106. It is expressed by various cells in the kidney, 
including M/MØ, mesangial cells, podocytes, and tubular cells107-111. Recent studies in 
experimental glomerulonephritis model have demonstrated that CCL2/CCR2 system 
plays an important role in the pathogenesis of crescent formation and progressive 
tubulo-interstitial lesions via M/MØ recruitment112. There are numerous evidences 
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suggesting the role of this chemokine in kidney diseases of various etiologies. For 
example, unilateral ureteral obstruction in rats increased the urinary CCL2 levels which 
are correlated with the degree of obstruction113. The presence of collagen types III and 
IV deposits in mesangial region and interstitial infiltration of M/MØ in experimental 
obstructive uropathy model indicate the role of CCL2 in the pathophysiology of kidney 
diseases114. It is also postulated that the degree of albuminuria is proportional to the 
active tubular chemokine expression in the proximal tubules115.  
 
Role of CCL2/MCP-1 in diabetic nephropathy 
Almost all components of the diabetic milieu induce the over expression of 
CCL2 in renal cells. Previous studies have demonstrated the role of CCL2 and its 
receptor CCR2 in the pathogenesis of DN. In patients with T2 DN, increased urinary 
excretion of CCL2 was correlated with CD68- positive infiltrated macrophages in the 
interstitium60. In addition, increased urinary CCL2 excretion was positively correlated 
with N-acetyl-β-D-glucosaminidase (NAG) excretion, a marker of tubular injury, 
implicating the role of CCL2 in tubulointerstitial damage116. This was evident by 
immuno-histochemical analysis and in situ hybridization, where a strong up regulation 
of CCL2 expression was found in tubular cells. It has also been shown that type 1 
diabetics with micro-albuminuria have increased plasma levels of CCL2117. Targeted 
deletion or inhibition of CCL2 in T1 or T2 diabetic mice prevented the 
glomerulosclerosis by blocking macrophage recruitment to the glomeruli118,119. In 
another study,  administration of anti-CCL2 antibodies protected the kidney from 
glomerular sclerosis and interstitial fibrosis120. Hemodynamic factors and renin 
angiotensin system (RAS) are also shown to induce CCL2 in the kidney121,122. Inhibition 
of angiotensin converting enzyme (ACE) or the mineralo-corticoid receptor also 
suppressed renal CCL2 production and improved the renal function in patients with 
T1D and T2D123-125.   
Numerous in vitro studies also revealed the role of CCL2 in diabetic kidney 
disease. High glucose treatment on endothelial cells isolated from diabetic subjects 
resulted in an increase of CCL2 release126. Several recent studies have also 
demonstrated that the cultured podocytes express CCR2 and thus, with exogenous 
CCL2 treatment, they reorganize their actin cytoskeleton and show increased motility, 
suggesting the direct effects of CCL2 on the glomerular cells127. In vivo, these signalling 
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changes translate into foot process effacement and podocytopenia20,128. In addition, 
CCL2 targets the slit diaphragm and induces the down regulation of nephrin via Rho-
kinase-dependent mechanisms129.  
Furthermore, studies have convincingly demonstrated the role of CCL2 in the 
development of DN. For example, in Leprdb/db mice and in streptozotocin (STZ) induced 
DN, CCL2 deficiency reduced renal monocyte and/or macrophage accumulation and 
abrogated the progression of diabetic renal injury118,119. Previous studies from our lab 
have documented that, in uninephrectomized db/db mice with T2D, blockade of CCL2 
with mNOX-E36 spiegelmer prevented the diabetic glomerulosclerosis and restored the 
GFR by inhibiting glomerular macrophage recruitment in late-stage of DN130. This 
study represents the CCL2 as promising therapeutic target in DN.  
Collectively, the pro-inflammatory chemokine, CCL2 promotes tissue 
inflammation and remodelling by recruiting and activating immune cells in DN.  
 
1.3.5 CXCL12/SDF-1 
The first identified lymphocyte homing chemokine, CXCL12, chemokine (C-X-
C motif) ligand 12, also known as stromal cell-derived factor-1 alpha (CXCL12α), is a 
unique homeostatic chemokine that signals through CXCR4 and CXCR7 (also known 
as RDC-1), but, with greater affinity to CXCR7131,132.  CXCL12 was originally isolated 
as a pre-B-cell growth-stimulating factor133 and subsequently shown to regulate trans-
endothelial migration, proliferation and differentiation of hematopoietic cells134. 
Moreover, it is important for the regulation of homeostatic trafficking and distribution 
of cells in the different compartments and sub-compartments of the immune system135-
137
.  
CXCL12 exhibits pro-inflammatory activities by recruiting immune cells to inflamed                              
tissues in autoimmune diseases such as rheumatoid arthritis (RA), nephritis, or murine 
lupus erythematosus138-140. On the other hand, CXCL12 also exhibits anti-inflammatory 
activities by augmenting antigen-specific T cell response141,142; suggesting that CXCL12 
acts as a double edged sword in mediating the inflammation.   
Furthermore, studies have shown that CXCL12/CXCR4 axis plays a key role in 
tissue repair and regeneration in a number of disease models like pancreatic beta cell 
loss in T1D 143, endovascular injury 144, and ischemic acute renal failure 145. For 
example, CXCL12 plays a protective role in renal pathogenesis by mediating tubular 
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epithelial cells (TECs) protection (by preventing TECs apoptosis) against ischemia-
reperfusion injury146, suggesting its role in tissue repair. In ischemic myocardium, 
CXCL12 executes a tissue protective and tissue regenerative function by decreasing the 
apoptosis and up-regulation of vascular endothelial growth factor (VEGF). The study by 
Yoshitsugu et.al. reported the key role of CXCL12/CXCR4 axis in the development of 
renal vasculature during embryogenesis, where CXCL12-secreting stromal cells 
surround CXCR4-positive epithelial components of early nephrons and blood vessels in 
the embryonic kidney147. In glomeruli, the CXCL12-secreting podocytes were found in 
close proximity to CXCR4 positive endothelial cells, demonstrating the role of 
CXCL12 in kidney development147,148. In addition, CXCL12 or CXCR4 KO embryos 
display defects in vascularization of the gastrointestinal tract, demonstrating the organ-
specific essential functions of CXCL12/CXCR4 in blood vessel formation149,150.  
The role of CXCL12 is not restricted to tissue repair and regeneration. Various studies 
demonstrate that the CXCL12 plays a key role in auto-immune diseases151. In lupus-like 
immune complex glomerulonephritis in NZB/NZW mice, CXCL12 blockade prevented 
the glomerulonephritis which was attributed to less autoantibody production and T cell 
recruitment to glomeruli, indicating its potential in ameliorating lupus nephritis140.  
In addition, CXCL12 promotes tumor metastasis in various organs expressing 
increased CXCL12 levels, including lymph nodes, lung, liver, and bone marrow; and 
also in lower expressing organs including small intestine, kidney, skin, brain, and 
skeletal muscle152. CXCL12 signaling also supports tumor growth either by promoting 
cancer cell survival or by promoting angiogenesis153. Recent studies have shown that 
inhibition of CXCL12 and CXCR4 decreased endothelial activation and organ injury 
and improved animal survival in shiga toxin induced renal injury where 
CXCR7/CXCR4/CXCL12 pathway plays a key role in the pathogenesis of uremic 
syndrome in human and mice154. It has been shown that, transgenic mice over 
expressing CXCR4 selectively in podocytes, caused proteinuria and glomerular crescent 
formation148. It is also evidenced by Balabanian et.al. that, glomerulonephritis was 
prevented by blocking CXCL12, and this activity was attributed to less podocyte 
proliferation and T-cell recruitment140. These studies suggest that CXCL12 creates a 
microenvironment for the homing of other cells including progenitor cells during repair 
and hence contributes to tissue regeneration.  
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Role of CXCL12 in diabetic nephropathy 
So far little is known about the role of CXCL12 in DN. By its name, 
“homeostatic” chemokines, CXCL12 display functions that are independent of tissue 
inflammation. Homeostatic chemokines are rather constitutively expressed, as they 
contribute to the physiological homing and migration of immune cells in bone marrow 
or lymphoid organs. For example, recent work from our laboratory has shown that, 
CXCL12 is constitutively expressed by podocytes and CXCL12 blockade with NOX-
A12 spiegelmer prevented diabetic glomerulosclerosis in a way that was independent of 
glomerular macrophage recruitment. CXCL12 blockade was shown to have a profound 
effect on podocyte count and proteinuria155. However, the mechanism underlying the 
protective effect of CXCL12 blockade on DN remained unclear. In addition, there was 
no increase in bone marrow-derived progenitor cells in kidneys of treated db/db mice 
observed. Thus, this enhancer effect on the capacity of intra-glomerular progenitors to 
restore podocytes in DN is suspected and hence should be studied further. 
 
 
1.4 Cathepsins 
The lysosomal/endosomal compartments are rich in proteases involved in 
degradation of proteins. The human genome encodes more than 600 proteases which are 
involved in various physiological functions including complement activation, signal 
transduction, intracellular house keeping and degradation of intra and extra cellular 
matrix proteins156. Cathepsins (Cats) are a class of globular proteases which are 
predominantly distributed in the lysosomal compartments involved in protein 
turnover157. The term “Cathepsin (Cat)” was derived from the Greek word, kata- 
“down” and hepsein “boil”, meaning “digest”. Normally Cats are located in lysosomes 
of the cells, but also reside in other compartments, such as phagosomes, and endosomes 
and they can be secreted in certain pathological conditions. Studies revealed that 
secreted forms of Cats are critical for degradation of the extracellular matrix during 
inflammatory or adaptive response156. Based on the mechanism of catalysis and 
structure, Cats are classified into three groups: cysteine, serine and aspartic Cats (Table 
4). 
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Table 4: Classification of cathepsins and their tissue distribution 
 
Adapted and modified from Ki Young Choi, et.al 2012 and Berdowska, 2004158,159 
 
1.4.1 Cysteine cathepsins  
The cysteine cathepsins (CCs) are predominantly endopeptidases, and are 
located intracellularly in endolysosomal vesicles. The majority of Cats fall into this 
category which consists of 11 Cats in humans and 10 of their counterparts in mice. In 
addition, eight additional Cats have been identified which are expressed only in the 
placenta of mice160 (Table 4). Cats activity is regulated intracellularly by stefins (stefin 
A and B) and extracellularly by cystatins (cystatin C) and kininogens161. CCs represent 
the major types of proteases abundantly found in mammals as well as in 
microorganisms (bacteria and virus)162. They are expressed throughout different types 
Family 
 
Group 
 
Organs showing the most expression  
 
Cysteine cathepsins 
CCs expressed 
ubiquitously 
 
 
 
 
 
 
 
 
CCs expressed in 
limited tissues 
 
 
 
 
 
 
 
Serine cathepsins 
 
 
Aspartic cathepsins 
 
 
Cathepsin B 
Cathepsin F 
 
Cathepsin H 
Cathepsin L 
Cathepsin O 
Cathepsin X 
Cathepsin C 
 
 
Cathepsin S 
 
Cathepsin K 
 
 
Cathepsin V 
Cathepsin W 
 
Cathepsin A 
Cathepsin G 
 
Cathepsin E 
 
Cathepsin D 
 
Liver, thyroid gland, kidney, spleen 
Heart, skeletal muscle, brain, testis, ovary, 
macrophages 
Liver, kidney, spleen 
Liver, thyroid gland, kidney 
Liver, kidney, placenta, ovary 
Liver, lung, kidney, placenta 
Kidney, placenta, lung, spleen, cytotoxic T 
lymphocytes 
 
Spleen, lymph nodes, antigen presenting cells, 
heart, cornea, testis, thymus 
Osteoclasts, macrophages, epithelial cells of 
gastrointestinal, respiratory and urinary tract of 
human embryo and fetus, adult human lung 
Cornea, testis, thymus 
Spleen, lymph nodes 
 
Testis, epididymis 
Human cerebral cortex, intervertebral discs 
 
Surface of epithelial mucus-producing cells of 
the stomach 
Retina, human epithelial breast cancer cells 
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of tissues and cells. Cats B, C, F, H, L, O, and Z are expressed constitutively and are 
thought to have housekeeping functions157, whereas, the expression of some CCs is 
regulated and is noticeably high in specific cell types. For example, Cat K is mainly 
found in osteoclasts 163, Cat W is expressed only in cytotoxic cells, in particular NK 
cells164,165, while Cat V is expressed only in humans and absent in mice166. Moreover, 
Cat S is selectively expressed in antigen presenting cells such as B-cells, macrophages 
and dendritic cells. However, it has been shown that the expression levels of Cats may 
alter in many patho-physiological conditions. It is well documented that CCs are over 
expressed in many cancers, cardiovascular and auto-immune diseases167,168.   
 
1.4.2 Pathophysiological role of cysteine cathepsins 
CCs participate in various physiological systems and are upregulated in many 
inflammatory disorders. Due to their increased expression and activity, CCs serve as 
candidate disease markers in many diseases including rheumatoid arthritis, multiple 
sclerosis, atherosclerosis and various cancers. It has been shown that Cats D, F, L, S and 
V are important participants in antigen processing and presentation, while Cats K, L and 
S play a key role in the development of atherosclerosis167,169,170. Moreover, the novel 
insights into CCs function in many human diseases have been gained by the generation 
of knockout and transgenic mice. Studies in mice deficient for Cat K or Cat S have 
confirmed a role of Cat K in bone remodelling and Cat S in MHC II presentation 
respectively171. In addition, Cat L-deficiency has been shown to cause development of 
myocardial fibrosis and phenotypes in skin, while Cat B-deficient mice exhibit reduced 
TNF-induced apoptosis of hepatocytes170. On the other hand, Cat S and B have been 
shown to be involved in the clearance of immune complexes and thereby protect the 
mice from neuronal death. Mice deficient in both Cat S and B exhibited reduced 
degradation of immune complexes and thereby inducing apoptosis of cerebral neurons, 
resulting in death172. In addition, these two Cats are also shown to be involved in 
tumour angiogenesis167. It is well documented that Cat B is involved in regulation of 
innate immunity via activation of inflammasomes173. Moreover, Cats B, H, K, L, and S 
are involved in other inflammatory conditions such as silicosis and sarcoidosis 
characterized by ECM degradation, suggesting the role of Cats in disease 
pathogenesis170. More recent studies have demonstrated that CCs play an important role 
in the development of renal diseases174. 
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1.4.3 Role of cysteine cathepsins in proteinuric kidney diseases 
In 1994, Shechter et.al. published that, in STZ induced rats, the development of 
diabetic renal hypertrophy with increased renal protein content was correlated with 
decreased activity of Cats B and L in kidneys175. In another study, the altered expression 
of Cats B, L and H in tubules of rats with polycystic kidney disease has also been 
demonstrated176. These two studies described that, the expression pattern of Cats varies 
at different stages of the disease for different Cats. But, until recently, the exact role of 
Cats in the kidney has not been well studied. In 2004, Reiser et.al. demonstrated that, 
Cat L is involved in the pathogenesis of podocyte foot process effacement (migration 
and detachment from GBM) which leads to proteinuria177. Later in 2007, Sanja et.al. 
demonstrated the direct role of Cat L in the development of proteinuric kidney 
diseases174. The authors demonstrated that dynamin is normally required to maintain the 
ultra-filtration barrier in kidneys, possibly via regulation of the actin cytoskeleton in 
podocytes. In LPS or puromycin amino nucleoside induced nephropathy, the induction 
of Cat L expression in podocytes cleaves the dynamin at an evolutionary conserved site, 
resulting in reorganization of the podocyte actin cytoskeleton, leading to podocytes loss 
and proteinuria174. In addition, various cytokines induce the up regulation of CCs in 
vitro and in vivo. It has been noticed that cytokines IL-4 and IL-13 induce the up-
regulation of Cat L in glomerular epithelial cells178. 
Recent studies revealed that Cat L serves as a potential and sensitive biomarker 
to assess the degree of kidney injury (gender specific) and management of chronic 
kidney disease179. On the other hand, immunostaining on bovine kidneys revealed that 
Cat S is localized in proximal tubules180. Further, studies in mice and humans have 
confirmed that, elevated levels of Cats S, L and B in plasma are associated with 
worsening of diabetes181.  
 
1.4.4 Cathepsin S 
Cat S, a major catalytic papain cysteine protease which is predominately present 
in the spleen, lymph nodes, and all antigen presenting cells, such as monocytes, 
macrophages, B cells and dendritic cells where it plays a pivotal role in antigen 
presentation170. Unlike other proteases, Cat S shows its proteolytic activity both at 
neutral and slightly basic pH and can function both inside and outside the lysosomes182. 
Its activity is tightly regulated by its endogenous inhibitor cystatin C183. Cat S activity is 
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reported to be involved in the pathophysiology of many inflammatory and auto immune 
diseases, including rheumatoid arthritis, osteoporosis, atherosclerosis and cancers. 
Indeed, recent studies indicate that increased serum levels of Cat S are associated with 
increased mortality risk in patients with cardiovascular and renal disease, cancer, 
obesity and diabetes184-186. In addition, Cat S inhibition in various inflammatory mouse 
models showed promising protective effects suggesting that, Cat S can be a potent 
therapeutic target for autoimmune and inflammatory disorders187,188.  
It was shown that macrophages express high levels of active Cat S, which 
contribute to extensive ECM remodelling. For example, Cat S deficiency or small 
molecule inhibitors reduced the atherosclerotic plaques by reducing the macrophage 
infiltration and accumulation, suggesting that Cat S plays an important role in leukocyte 
migration169,189. Recent studies have demonstrated that angiotensin II was found to 
stimulate the mRNA expression of Cat S in smooth muscle cells and modulated the 
inflammation and apoptosis in atherosclerosis190. Various factors and cytokines are 
known to induce Cat S in many other cell types including adipocytes, endothelial cells 
and smooth muscle cells. For example, various proinflammatory cytokines including 
TNF-α and IFN-γ are potent inducers of Cat S in endothelial cells and play a role in the 
degradation of extracellular elements such as laminin and collagens186,189.  
Apart from its potent proteolytic activity and mediating the inflammation, recent 
studies have shown that Cat S is differentially expressed during kidney and fetal lung 
development191. In contrast, Cat S activity has also been proposed to play a part in the 
development of cancer by tumor angiogenesis192. DNA microarray analysis revealed 
that in Ochatoxin A (OTA) nephropathy, proximal tubule cells (PTC) expressed high 
levels of Cat S, indicating the role of Cat S in the development of kidney diseases193.  
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1.5 Animal models of diabetic nephropathy 
Ideal animal models which provide an experimental system of unparalleled 
flexibility are very essential for studying any mammalian diseases. The advantage of 
using mouse model attributes to their fully studied genome, the lower maintenance, cost 
effectiveness, and short reproductive cycles. The use of experimental models of DN has 
provided valuable information regarding many aspects of DN, including 
pathophysiology, progression, and new therapeutic strategies194.  
According to “The Animal Models of Diabetic Complications Consortium” 
(AMDCC), any mouse models used to study human diabetes and diabetic complications 
should meet the minimum criteria and exhibit >50% decline in GFR over the lifetime of 
the animal, >10-fold increase in albuminuria compared with controls for that strain at 
the same age and gender, and pathology of kidneys (advanced mesangial matrix 
expansion, ± nodular sclerosis mesangiolysis, any degree of arteriolar hyalinosis, 
glomerular basement membrane thickening by >50% over baseline and 
tubulointerstitial fibrosis)195.  
In recent years, there were several genetic mouse models of diabetes (Table 5) 
established and the best characterized model is LepRdb/db type 2 diabetic mice. The 
db/db mouse is the most widely used mouse model of T2D. First described in 1966 in 
Jackson laboratories, the db gene encodes a G-to-T point mutation of the leptin receptor, 
which is transmitted in an autosomal recessive fashion. This leptin receptor mutation 
(LepRdb/db) results in abnormal splicing and a defective receptor for the adipocyte-
derived hormone leptin which is altered in the hypothalamus. Due to this fact, these 
mice do not feel a sense of satiety due to hyperphagia and develop obesity with high 
leptin levels and hyper-insulinemia. Kidney function in these mice on the C57BL/KS 
background has been intensively investigated and exhibits some features similar to early 
human DN, class I to III. DN in the C57BL/KsJ (db/db) mouse is initially expressed as 
increased urinary albumin excretion at the age of 8 weeks without evidence of 
glomerular lesions by light microscopy. After 16 week of age, there is a very consistent 
three fold increase in mesangial matrix expansion and at about 6 month of life, signs of 
diabetic kidney damage are visible. The animals show an increasing necrosis and 
tubular dilatation, tubular atrophy, interstitial fibrosis and leukocyte infiltrates.  
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Table 5: List of mouse models studied for diabetic nephropathy 
 
Animal model  Strains reported              Diabetic type  
 
Streptozotocin  C57BL/6J, C57BLKS,          Type I 
  Balb/c, ICR, 
  DBA2, ROP 
 
Encephalomyocarditis-      DBA, Balb/c                  Type I 
-virus D variant   
 
Ins2 Akita                C57BL/6, C3H                Type I 
 
NOD                     Inbred line derived from         Type I 
                         ICR (out bred line) 
    
db/db  C57BL/6, C57BLKS,           Type II 
                         DBA, FVB, CBA   
 
ob/ob  C57BL/6,                     Type II 
  DBA2, FVB/N 
 
Agouti (Ay)               KK, C57BL/6                 Type II 
                         C3H, FVB 
 
High-fat diet              C57BL/6 is a main             Type II 
                         -susceptible strain 
  
db/db eNOS -/-            BKS                         Type II 
 
NONcNZO10/LtJ          NON/LtJ+NZO/HlLt           Type II 
 
BTBRob/ob                 BTBR                        Type II 
 
GIPRdn transgenic          CD1                         Type II 
 
GLUT1 transgenic         C57BL/6J                     Non-diabetic 
                                                      -transgenic mice 
podIR -/- (podocin or       Mixed genetic background - 
- nephrin promoter)         (C57BL/6, 129/SV and  
      FVB)  
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1.6 Spiegelmers-next generation Aptamers 
To achieve CCL2 and CXCL12 antagonism, we used RNA-aptamers 
(Spiegelmer), a patented technology of NOXXON Pharma (Berlin). RNA-aptamer 
binds to the active site of target chemokines and makes them biologically non-
functional.  
An aptamer is a nucleic acid structure that can bind to a target molecule 
conceptually similar to an antibody that recognizes an antigen. Aptamers have binding 
characteristics similar to peptides or antibodies, with affinities in the low nanomolar to 
the picomolar range. However, there are several drawbacks to aptamers as useful 
therapeutic products. As relatively small molecules, aptamers demonstrate circulating 
half-lives in vivo in the order of minutes. This situation can be addressed by attaching 
large inert molecules to aptamers (e.g. polyethylene glycol) to reduce their elimination 
via the kidney and hence increase their presence in the circulation. Nevertheless, 
aptamers, as natural nucleic acid polymers, are prone to rapid degradation by nucleases 
that are present in all tissues in the body.  
Spiegelmers are bio-stable aptamers, have all the diverse characteristics of 
aptamers but possess a structure that prevents enzymatic degradation. While aptamers 
are created from the natural D-nucleotides, which are recognized by the nucleic acid 
degrading enzymes, Spiegelmers are synthesized as the mirror image L-oligonucleotide 
and are not degraded by any nucleases since there are no such enzymes in the body 
capable of interacting with these unnatural molecules196. Spiegelmer technology is 
based on the simple concept that if an aptamer binds its natural target, the mirror image 
of the aptamer will identically bind the mirror image of the natural target (Figure 5). 
The process of aptamer selection is carried out against the mirror image target protein; 
an aptamer against this unnatural mirror image is obtained. More important, this 
Spiegelmer is now resistant to nuclease degradation. Spiegelmers should not be 
confused with antisense RNAs as in that, they do not directly interfere with 
transcription or translation of their target molecules 196. They are designed to bind 
specifically to extracellular proteins, either a receptor or its ligand, similar to the 
behaviour of a monoclonal antibody, aptamer or peptide. Spiegelmers appear to be non-
immunogenic, even under the most inductive conditions for antibody formation in 
rabbits. These molecules are termed “Spiegelmer” from the German word “Spiegel” 
meaning “mirror”. 
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Figure 5: Representation of Spiegelmer generation. L-enantiomer of the target is processed to get the 
selective binding D-aptamer. Highly selective D-aptamer for mirror image (L-target) is then amplified 
and then mirrored to get L-aptamer which has the selective binding property for natural D-target. (Taken 
from www.noxxon.net) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Representation of Spiegelmer stability. Left panel with D-enantiomeric RNA which degrades 
in seconds when incubated in human plasma at 37°C., while L-enantiomeric RNA is stable even at 60 h 
of incubation in human plasma (right panel) (Taken from www.noxxon.net) 
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Summary of Spiegelmer properties  
 
• High binding specificity to their target  
• Comparable binding affinity as antibodies (low nanomolar-picomolar)  
• Stable in human plasma and after injection into animals  
• Non-immunogenic  
• Low toxicity (target-based)  
• Synthesized using standard chemistry (scalable)  
• No biological contaminants  
• Easy to formulate (polar) with excellent solubility 
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2. Research hypothesis 
Targeting chemokines 
Previous work from our laboratory has shown that CCL2/MCP-1 and 
CXCL12/SDF-1 both contribute to glomerulosclerosis in mice with T2DM through 
different mechanisms. CCL2 mediates macrophage-related inflammation, whereas 
CXCL12 contributes to podocyte loss. Inhibition of CCL2 by mNOX-E36 showed the 
protection from diabetic glomerulosclerosis and restored the GFR by preventing 
glomerular macrophage recruitment. Thus, CCL2 blockade prevents the progression of 
DN by interfering with macrophage-driven glomerular inflammation. Inhibition of 
CXCL12 by NOX-A12 significantly reduced the degree of glomerulosclerosis, 
increased the number of podocytes, prevented the onset of albuminuria and maintained 
the peritubular vasculature without affecting glomerular macrophage infiltration. 
Nevertheless, the mechanism underlying the protective effect of CXCL12 blockade on 
DN remains unclear. Therefore, the aim of the study was to evaluate the effect of dual 
blockade of both chemokines on the progression of DN. We hypothesized that dual 
blockade of both chemokines; compared to monotherapies of either CCL2 or CXCL12 
antagonists, might have beneficial effects in an accelerated mouse model of DN. 
 
Targeting cathepsins 
Cat S is a member of cysteine protease family involved in pathogenesis of 
various inflammatory and auto-immune diseases. Various pro-inflammatory cytokines 
upregulate the Cat S expression in various cells, especially in macrophages and promote 
their infiltration to the inflamed tissue. In addition, Cat S is also known to degrade the 
extracellular matrix in various compartments and promote vascular remodelling. 
Previous studies with inhibitors for Cats other than Cat S confirmed their role in the 
progression of kidney diseases, but, so far, the role of Cat S in DN has not been 
explored. Cat S inhibition was immunosuppressive in several models of autoimmune 
diseases, implicating its use as a potential target to treat autoimmune and inflammatory 
diseases. Since inflammation and vascular damage are the major mediators in the 
progression and development of DN, we hypothesized that Cat S inhibition might be 
protective in progressive DN. 
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3. Material and methods 
 
3.1 Materials 
 
Instruments and chemicals 
 
Instruments 
 
Anaesthesia  
Isoflurane anaesthesia chamber Harvard Anaesthesia system, UK. 
 
Balances  
Analytic balance, BP110S Sartorius, Göttingen, Germany 
Mettler PJ 3000 Mettler-Toledo,Greifensee, Switzerland 
 
Cell culture incubators 
Type B5060 EC-CO2 Heraeus Sepatech, München, Germany 
 
Centrifuges 
Heraeus, Minifuge T VWR International, Darmstadt, Germany 
Heraeus, Biofuge primo                   Kendro Laboratory Products GmbH, Hanau, 
Germany 
Heraeus, Sepatech Biofuge A Heraeus Sepatech, München, Germany 
 
ELISA reader 
Tecan, GENios Plus Tecan, Crailsheim, Germany 
 
Fluorescence microsocopes 
Leica DC 300F                               Leica Mycrosystems, Cambridge, UK  
Olympus BX50                          Olympus Microscopy, Hamburg, Germany 
 
TaqMan sequence detection system  
ABI prism ™ 7700 sequence detector PE Biosystems, Weiterstadt, Germany  
RT-PCR Light cycler 480, Roche, Germany 
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Other equipment 
 
Cryostat RM2155 Leica Microsystems, Bensheim, Germany 
Cryostat CM 3000                           Leica Microsystems, Bensheim, Germany 
Glucometer accu check sensor Roche, Mannheim, Germany 
Homogenizer ULTRA-TURRAX T25 IKA GmbH, Staufen, Germany 
Microtome HM 340E Microm, Heidelberg, Germany 
Nanodrop PEQLAB Biotechnology GmbH, Erlangen,  
 Germany 
pH meter WTW  WTW GmbH, Weilheim, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Vortex Genie 2™                              Bender&Hobein AG, Zurich, Switzerland 
Water bath HI 1210 Leica Microsystems, Bensheim, Germany 
 
Chemicals and reagents 
 
RNeasy mini kit Qiagen GmbH, Hilden, Germany 
RT-PCR primers                              Metabion, Martinsreid, Germany 
 
Cell culture  
DMEM-medium Biochom KG, Berlin, Germany  
Dulbecco’s PBS (1X)  PAA Laboratories GmbH, Cölbe, Germany 
FSC Biochom KG, Berlin, Germany 
Penicillin/streptomycin (100X) PAA Laboratories GmbH, Cölbe, Germany 
RPMI-1640 medium GIBCO/Invitrogen, Paisley, Scotland, UK 
Trypsin/EDTA (1X)  PAA Laboratories GmbH, Cölbe, Germany 
 
Antibodies  
7/4 AbD Serotec, Düsseldorf, Germany 
β-Actin Cell signalling, Danvers, MA 
Cat S R&D Systems, Minneapolis, MN, USA 
CD3  BD Pharmingen, Hamburg, Germany 
CD11b BD Pharmingen, Hamburg, Germany 
CD45  BD Biosciences, Mannheim, Germany 
F4/80 FITC Caltag Laboratories, Bulingame, CA, USA 
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Goat anti-rat HP Dianova, Hamburg, Germany  
HP linked anti-Rabbit secondary Ab Cell signalling, Danvers, MA 
Ki-67  Dako Deutschland GmbH, Hamburg, Germany 
Ly6C+ BD Pharmingen, Hamburg, Germany 
Ly6G BD Pharmingen, Hamburg, Germany 
Mac2 Cederlane, Ontario, Canada 
Rat anti-mouse neutrophils AbD Serotec, Düsseldorf, Germany 
Rat anti-mouse CD74 BD Biosciences 
WT-1  Santa Cruz Biotechnology, CA, USA 
 
ELISA kits  
Albumin  Bethyl Laboratories, TX, USA 
MCP-1/CCL2 R &D Systems, Minneapolis, MN, USA 
Creatinine FS DiaSys Diagnostic System, GmbH, 
 Holzheim, Germany 
CXCL12 R &D Systems, Wiesbaden, Germany 
 
Chemicals  
 
Acetone                                          Merck, Darmstadt, Germany  
Acrylamide 30% Carl Roth GmbH, Karlsruhe, Germany 
AEC substrate packing Biogenex, San Ramon, USA  
Beta-mercapto ethanol Roth, Karlsruhe, Germany 
Bovine Serum Albumin                    Roche Diagnostics, Mannheim, Germany 
Calcium chloride Merck, Darmstadt, Germany  
Calcium dihydrogen phosphate Merck, Darmstadt, Germany 
Calcium hydroxide Merck, Darmstadt, Germany 
DAPI Sigma-Aldrich, Steinheim, Germany 
DEPC Fluka, Buchs, Switzerland 
Diluent C for PKH26 dye Sigma-Aldrich Chemicals, Germany  
DMSO Merck, Darmstadt, Germany 
EDTA Calbiochem, SanDiego, USA 
Eosin Sigma, Deisenhofen, Germany 
Ethanol Merck, Darmstadt, Germany 
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Formalin Merck, Darmstadt, Germany  
Hydroxyethyl cellulose Sigma-Aldrich, Steinheim, Germany 
HCl (5N) Merck, Darmstadt, Germany 
Inulin-FITC Sigma-Aldrich, Steinheim, Germany 
Isopropanol Merck, Darmstadt, Germany 
MACS-Buffer Miltenyi Biotec, Bergisch Gladbach, Germany 
Oxygenated water DAKO, Hamburg, Germany  
Penicillin Sigma, Deisenhofen, Germany 
Phosphate Buffer Saline (DPBS) PAN Biotech GmbH, Germany 
Roti-Aqua-Phenol Carl Roth GmbH, Karlsruhe, Germany 
Skim milk powder Merck, Darmstadt, Germany 
Sodium acetate Merck, Darmstadt, Germany  
Sodium chloride                              Merck, Darmstadt, Germany 
Sodium citrate Merck, Darmstadt, Germany 
Sodium dihydrogenphosphate           Merck, Darmstadt, Germany 
Streptomycin                                  Sigma, Deisenhofen, Germany 
TEMED Santa Cruz Biotechnology, Santa Cruz, CA 
Tissue freezing medium                   Leica, Nussloch, Germany 
Trypan Blue Sigma, Deisenhofen, Germany 
Xylol                                             Merck, Darmstadt, Germany  
 
Miscellaneous 
 
Anti-FITC micro beads Miltenyi Biotec, Germany 
Cat S activity assay kit BioVision, Inc., Milpitas, CA, USA 
Cell death detection (TUNEL) kit Roche Diagnostics, Mannheim, Germany 
CellTiter 96 proliferation assay Promega, Mannheim, Germany 
Needles   BD Drogheda, Ireland 
Pipette’s tip 1-1000 µL Eppendorf, Hamburg, Germany 
Plastic histo-casettes NeoLab, Heidelberg, Germany 
Pre-separation filters Miltenyi Biotec, Bergish Gladbach,  
    Germany 
SuperFrost Plus microscope slides Menzel-Gläser, Braunschweig, Germany 
Syringes                                    Becton Dickinson GmbH, Heidelberg, Germany 
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Tissue culture dishes 100x20 mm TPP, Trasadingen, Switzerland 
Tissue culture dishes 150x20 mm TPP, Trasadingen, Switzerland 
Tissue culture dishes 35x10 mm Becton Dickinson, Franklin Lakes, NJ, USA 
Tissue culture flasks 150 cm2 TPP, Trasadingen, Switzerland 
Tubes 15 and 50 mL TPP, Trasadingen, Switzerland 
Tubes 1.5 and 2 mL TPP, Trasadingen, Switzerland 
• All other reagents were of analytical grade and are commercially available from 
Invitrogen, SIGMA or ROTH. 
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3.2 Methods 
 
3.2.1 Part I 
 
3.2.1 Animal studies 
 
Male diabetic C57BLKS db/db mice or non-diabetic C57BL/6 mice 5-6 week 
old were obtained from Taconic (Ry, Denmark) and housed in filter top cages with a   
12 hrs dark/light cycle. All animals had unlimited access to food and water throughout 
the study duration. At the age of 6 weeks uninephrectomy (1K mice) or sham surgery 
(2K mice) was performed as described below. All animal experiments were approved 
by the local government authorities. 
 
 
Animal model-Uninephrectomized db/db mice 
 
Surgical procedure of Uninephrectomy 
 
Uninephrectomy (1K mice) or sham surgery (2K mice) was performed under 
general anaesthesia using isoflurane. Anesthetized mice were positioned laterally on the 
operation bed. Under deep anaesthesia a flank incision of about 1-1.5 cm was made on 
the dorsolateral side just below the thoracic cage so as to reach kidney easily. A silk 
suture (2-0) was passed around the right kidney and after tying off all blood vessels and 
ureter the kidney was rapidly excised out using a curved scissors. In sham operated 
group of mice, the kidney was left in situ. Skin incision was closed with silk suture and 
wound clamps (Figure 7). All mice received analgesic (1 drop of Novaminsulfon, 
Ratiopharm GmbH, Germany, 1:200, orally administered) before and after surgery. 
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Figure 7: Schematic representation of uninephrectomy 
A: Making flank incision.  
B: Tying off the kidney’s vessels and ureter with silk suture. 
C: Excision of the kidney after ligation.  
D: Wound closing with silk suture and wound clamps. 
     This image was kindly provided by Dr. Volha Ninichuk. 
 
3.2.2 Route and rationale of test material administration  
 
The chosen route of administration was subcutaneous, as the animals can tolerate 
a large number of subcutaneous administrations quite better than numerous intra-
peritoneal injections. Also, handling is easier and the compound exposure is longer in 
the circulation by this route.  
 
Test substance and formulation  
 
Spiegelmer     Sequence 
mNOX-E36 (CCL2 antagonist) 5' GGCGACAUUGGUUGGGCAUGAGGCGA 
GGCCCUUUGAUGAAUCCGCGGCCA-3' 
NOX-A12 (CXCL12 antagonist) 5'-GCGUGGUGUGAUCUAGAUGUAUUGG   
CUGAUCCUAGUCAGGUACGC-3' 
revNOX-A12 (control antagonist) 5'-GCAUGGACUGAUCCUAGUCGGUUA 
UUAGAUCUAGUGUGGUGCG-3' 
To distinguish possible target-specific from unspecific substance class effects, a non-
functional spiegelmer with the reverse sequence of NOX-A12 was used. The 
A B
C D
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Spiegelmers were modified with 40 kDa branched polyethylene glycol (PEG) at the 
3'-end (mNOX-E36) or at the 5'-end (NOX-A12 and revNOX-A12). mNOX-E36 and 
NOX-A12 bind to CCL2 and CXCL12 respectively, with sub-nanomolar affinities. All 
spiegelmers were dissolved in isotonic 5% glucose solution for administration.  
 
 
3.2.3 Study design 
 
At the age of 4 months, 1K db/db mice with documented blood glucose levels 
>11 mmol/L and albumin/creatinine ratios >3 (ratio in age-matched wild-type mice = 
0.1) were divided into four groups (n = 10-12) each of these groups received either nil 
(no injections) or subcutaneous injections of 50 mg/kg NOX-A12, mNOX-E36 or 
control Spiegelmer in 5% glucose or 5% glucose itself as a vehicle control, on every 
other day (Figure 8). This dose corresponds to 13.4 mg/kg NOX-A12 or 14.4 mg/kg 
mNOX-A36 if based on the oligonucleotide part of the molecule as anhydrous free acid. 
The treatment dose and injection intervals were comparable to our previous db/db 
mouse studies with similar formulations of Spiegelmers targeting these chemokines. 
Treatment was continued for 8 weeks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Treatment protocol I 
    
↓↓↓ ↓↓↓ 
mNOX-E36-PEG (anti-CCL2) 
 mNOX-A12-PEG (anti-CXCL12) 
mNOX-A12-PEG + mNOX-E36-PEG 
revNOX-A12 
 Vehicle  (5% Glucose) 
   (50mg/kg, s.c every other day) 
 
 
0          1           2             3                                                                                                                                             4                        5                                                                                                                                                                                                           6 
Month of life 
Uninephrectomy at 6week 
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3.2.4 Glomerular filtration rate  
 
 
5% FITC-inulin was dissolved in two ml of 0.9% NaCl facilitated by heating the 
solution in boiling water. Mice were anesthetized using isoflurane for approximately 20 
seconds. 5% FITC-inulin (3.74 µL/g body weight) was injected retroorbitally under 
anaesthesia within 10 seconds. Under general anaesthesia, blood was drawn from the 
retro orbital plexus at 5, 10, 15, 20, 35, 60 and 90 min post administration. Since pH 
significantly affects FITC fluorescence value, each plasma sample was buffered to pH 
7.4, by mixing 10 µL of plasma with 40 µL of 500 mM HEPES (pH 7.4). The titrated 
samples were then loaded onto a 96-well plate at 50 µL sample/well. Fluorescence was 
determined with 485 nm excitation, and read at 538 nm emission. 
A two-compartment clearance model may be employed for the calculation of 
GFR. In a two-compartment model used, as depicted in Figure 9, the initial, rapid decay 
phase represents redistribution of the tracer from the intravascular compartment to the 
extracellular fluid. Systemic elimination is also occurs, but the distribution process is 
relatively dominant during this initial phase. During the later phase, slower decay in 
concentration of the tracer systemic clearance of the tracer from the plasma 
predominates. At any given time (tX), the plasma concentration of the tracer (Y) equals 
to Ae -αtx + Be -βtx +Plateau. 
 
 
 
 
 
 
Figure 9: Representation of two phase regression curve 
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The parameters of above equation could be calculated using a non-linear regression 
curve-fitting program (GraphPad Prism, GraphPad Software, Inc., San Diego, CA). 
GFR was calculated using the equation: 
GFR= I/(A/α + B/β) 
Where I is the amount of FITC-inulin delivered by the bolus injection; A (Span1) and B 
(Span2) are the y -intercept values of the two decay rates, and α and β are the decay 
constants for the distribution and elimination phases, respectively. 
 
Plasma, urine and tissue collection  
 
At 24 weeks of age, after treatment, blood samples were collected under 
isoflurane anaesthesia. Small blood samples (around 100µL) were collected in micro 
centrifuge tubes containing EDTA (10 µL of 0.5 M solution per 200 µL of blood) and 
plasma was separated by centrifugation at 10,000 rpm for 5 min and stored at -20 °C 
until used for different cytokine estimations. Urine samples were collected at every 
alternate week from 16 weeks of age till 24 weeks and stored at -20 °C for further 
analysis. Tissues were harvested for histopathological evaluation and RNA analysis at 
the end of the treatment period. All samples were collected 3-4 h after the last 
Spiegelmer injection.  
 
 
3.2.5 Plasma CCL2 and CXCL12 ELISA 
 
Plasma chemokines were estimated using commercial ELISA kits following the 
manufacturer’s instructions. 
 
CCL2 ELISA 
 
Protocol (in brief)  
1) The NUNC 96 well ELISA plate was captured overnight at 4 °C with the capture 
antibody (1: 250 dilution) in coating buffer (Phosphate buffer, pH 6.5) 
2) Next day the plates were washed 3 times with the wash buffer (PBS with 0.05% 
Tween- 20) and blocked with the assay diluent (PBS with 10% FBS) for 1 h. 
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3) Again the wash steps were repeated 3 times followed by addition of standards, 
samples and sample diluent (blank) into the wells and incubated at RT for 2 h. 
4) This was followed by 5 washes. 
5) Then the detection antibody (1:250 dilution) diluted in assay diluent was added and 
incubated the plate at RT for 1 h. 
6) The wells were washed again for 7 times and incubated with 100 µL of TMB 
substrate (1:1 mixture, A and B) for 10-20 min, followed by addition of 100 µL 2 N 
H2SO4.  
7) The absorbance was read at 450 nm using a spectrophotometer. 
 
CXCL12 ELISA 
 
Plasma levels of CXCL12 were measured using commercial kit from R&D 
system and the materials provided and used are as follows,  
Protocol (in brief)  
1) To the pre-coated 96 well plate, added 50 µL of standards, samples and sample 
diluent (blank) and incubated at RT for 2 h. 
2) Washed the plate 3 times  
3) Then incubated the plates for 1 h at RT with conjugated detection antibody diluted 
in assay diluent.  
4) Repeated the step2. 
5) Added 200 µL of substrate solution and incubated for 10-20 min, followed by 
addition of 50 µL of stop solution.  
6) The absorbance was read at 450 nm using a spectrophotometer. 
 
 
3.2.6 Urine albumin/creatinine ratio (UACR) 
 
Urine albumin ELISA 
 
Urinary albumin levels were determined using albumin ELISA kit from Bethyl 
Laboratories following manufacturer’s instructions. Generally albumin levels in urine 
samples from db/db mice were quite high, so urine samples were diluted 1000 times 
with water before estimation.  
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Protocol (in brief)  
1) The NUNC 96 well ELISA plate was captured overnight at 4 °C with the capture 
antibody (1:100 dilution) in coating buffer (carbonate-bicarbonate pH 9.6) 
2) Next day the plates were washed 3 times with the wash buffer (Tris, NaCl with 
0.05% Tween- 20) and blocked with the blocking solution (Tris, NaCl with 1% 
BSA, pH 8) for 1 h  
3) Again the wash steps were repeated 5 times followed by addition of standards, 
samples and sample diluent (blank) into the wells and incubated at RT for 2 h. 
4) This was followed by 5 washes. 
5) Then the HP-conjugated detection antibody (as suggested) diluted in assay diluent 
was added and incubated the plate at RT for 1 h. 
6) The wells were washed again for 7 times and incubated with 100  µL of TMB 
substrate (1:1 mixture, A and B) for 10-20 min until colour reaction developed, 
followed by  addition of 100  µL 2N H2SO4.  
7) The absorbance was read at 450 nm using a spectrophotometer. 
 
Urine creatinine measurement 
 
Urinary creatinine levels were measured using enzymatic reaction (Jaffe’ reaction 
using biochemical kit from Diasys). Urine samples were diluted 5 to 10 times 
(depending on the expected concentration range) with distilled water. Different dilutions 
of standard were prepared using the stock provided with the kit. Working monoreagent 
was prepared by mixing 4 part of reagent 1 (R1) and 1 part of reagent 2 (R2) provided 
with the kit. 10 µL of each of the diluted samples and standards were added to a 96 well 
plate with flat bottom (Nunc maxisorb plate). 200 µL of monoreagent was added to each 
well and absorbance for was read at    490 nm immediately after and 1 (A1) and 2 (A2) 
min of addition using ELISA plate reader. The change in absorbance (∆ A) was 
calculated   as ∆A = [(A2 – A1) sample or standard] – [(A2 – A1) blank]. Creatinine 
content of samples was calculated as: 
 
Creatinine (mg/dL) = ∆A sample /∆A standard * Concentration of standard (mg/dL) 
 
 
 
 
 
Chemokines and Cysteine proteases in diabetic kidney disease                                                        Methods                                                                 
 
41 
 
Urinary albumin to creatinine ratio  
 
Urinary albumin to creatinine ratio was calculated after converting values for 
albumin and creatinine to similar units (mg/dL). Albumin content for each sample 
calculated (mg/dL) was divided by creatinine content (mg/dL) for the same sample.  
 
 
3.2.7 RNA isolation, cDNA preparation and real-time quantitative (RT-PCR) 
 
Renal tissue from each mouse was snap frozen in liquid nitrogen and stored at -
80 °C. Real time RT-PCR was performed in pooled samples (5 animals from each 
group) on a TaqMan ABI 7700 Sequence Detection System using a heat activated 
TaqDNA polymerase (Amplitaq Gold, PE Biosystems). Controls comprising ddH2O 
were negative for target and housekeeper genes. Primers were from Metabion, 
Martinsried, Germany. From each animal total renal RNA preparation and reverse 
transcription were performed as described.  
 
Isolation of RNA from tissues  
 
When animals were sacrificed on termination of the study, small parts of tissue 
from each mouse were preserved in RNA-later and stored at -20 °C until processed for 
RNA isolation. RNA isolation was carried out using RNA isolation kit. In short, tissues 
(30 mg) preserved in RNA-later were homogenized using blade homogenizer for 30 s at 
14500 rpm in lysis buffer (600 µL) containing β-mercaptoethanol (10 µL/mL). The 
homogenate was centrifuged at 15000 rpm for 3 min and 350 µL of supernatant was 
transferred to fresh DEPC-treated tube. To this, equal amount (350 µL) of 70 % ethanol 
was added and whole mixture was loaded on RNA column and processed for RNA 
isolation as per the manufacturer’s instruction. Isolated RNA was stored at -80 °C until 
further used.  
 
 
RNA quantification and purity check  
 
For quantification isolated RNA samples were diluted in DEPC water (2 µL of 
RNA + 98 µL of DEPC water, 50 times dilution) and absorbance was measured at two 
wavelengths 260 nm and 280 nm. 
Amount of RNA (µg/ µL) = O.D. at 260 nm * 40 * 50 (dilution factor)/ 1000  
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The ratio of optical densities at 260 nm and 280 nm is an indicator for RNA purity 
(indicative of protein contamination in the RNA samples). Only samples with a ratio of 
1.8 or more were considered to be of acceptable quality.  
 
RNA integrity check  
 
Further quality check (if necessary) was performed using a denaturing RNA gel. 
In short, 2% Agarose gel with Ethidium-bromide was casted, RNA samples were mixed 
with RNA loading buffer (4:1 ratio) (Sigma) and were loaded on the gel. 
Electrophoresis was carried out at constant volt (70-100 V) using MOBS running buffer 
for 1  h and the gel was read on a gel documentation apparatus under UV lamp. RNA 
samples showing a single bright band were considered to be of good quality. Loss of 
RNA integrity could be detected as smear formation in the agarose gel (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     Figure 10: Representative agarose gel for RNA integrity check 
 
 
cDNA synthesis 
 
The RNA samples isolated according to the procedure detailed above were 
diluted in DEPC water to a concentration of 1 µg/20 µL. The master mix was made to a 
volume of 15 µL and added to 2 µg/30 µL RNA samples were taken in separate DEPC 
treated micro centrifuge tubes which were mixed and placed at 42 °C on a thermal 
shaker incubator. After 90 min, the cDNA samples were collected and stored at -20 °C 
until use for real-time RT-PCR analysis.  
The master contains the following components: 9 µL of 5x buffer (Invitrogen, 
Karlsruhe, Germany), 1 µL of 25mM dNTP mixture (Amersham Pharmacia Biotech, 
Freiburg, Germany), 2 µL of 0.1 M DTT (Invitrogen, Karlsruhe, Germany), 1 µL of 40 
U/µL RNasin (Promega, Mannheim, Germany), 0.5 µL of 15 µg/mLlinear acrylamide 
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(Ambion Ltd, Cambridgeshire, UK), 0.5 µL of Hexanucleotide (Roche, Mannheim, 
Germany) and 1 µL of Superscript (Invitrogen, Karlsruhe, Germany) or ddH2O in case 
of controls.  
 
Real-time quantitative (TaqMan) RT-PCR  
 
The cDNA samples prepared as described above were diluted 1:10 a dilution for the 
real-time RT-PCR. The following protocol used for RT-PCR: Pre-incubation was carried 
out for 5 min at 95 °C to ensure the activation of the polymerase and complete 
denaturation of cDNA samples. This was followed by amplification for 40 cycles, each 
comprising of 15 seconds incubation at 95 °C and 45 seconds incubation at 60 °C. For 
melting curve initial 95 °C for 5 s followed by 65 °C for 1 min with continuous heating 
was used. The RT-PCR for the reference genes (18S rRNA) was carried out under 
similar conditions. The CT values were calculated using the Light Cycler 480 and the 
results were normalized with respective reference gene expression for each sample. In 
all cases controls consisting of ddH2O were negative for target or reference genes. All 
designed SYBR green primers for all genes evaluated were obtained from Metabion 
(Martinsried, Germany) (Table 6). All gene expression values were normalized using 
18s RNA as a house keeping gene. All primers used for amplification were from 
Metabion (Martinsried, Germany).  
 
 
3.2.8 In vitro studies 
 
Normal renal tissues were obtained from four patients nephrectomized because of renal 
cell carcinoma, in agreement with the Ethical Committee on human experimentation of 
the Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 293 (HEK-293) were 
purchased from ATCC (Manassas, VA, USA) and cultured as specified by the supplier. 
The HACAT cell line was a gentle gift of Dr. Rosa Mancina (Florence, Italy). Human 
renal progenitors were obtained by immune-magnetic sorting for CD133 after depletion 
of digested total renal cell suspensions for CD45 and podocalyxin, as previously 
described18. Primary cultures of human renal progenitors were >99% positive for 
CD133 and CD24 co-expression, as checked by FACS analysis. Podocyte markers were 
absent. For podocyte differentiation, cells were treated for 2 days with VRAD medium 
(vitamin D3, retinoic acid and dexamethasone-supplemented DMEM) as previously  
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Table 6: Oligonucleotide primers used for SYBR-Green RT-PCR 
 
 
Target                 Primer sequence 
 
CCL2                 Reverse   :  CCTGCTGTTCACAGTTGCC             
                      Forward   :  ATTGGGATCATCTTGCTGGT 
CXCL12              Reverse   :  TTTCAGATGCTTGACGTTGG      
Forward   :  GCGCTCTGCATCAGTGAC 
TNF                   Reverse   :  AGGGTCTGGGCCATAGAACT     
                      Forward   :  CCACCACGCTCTTCTGTCTAC 
iNOS                 Reverse   :  TGAAGAAAACCCCTTGTGCT    
                      Forward   :  TTCTGTGCTGTCCCAGTGAG 
Nephrin (NPHS1)       Reverse   :  CTCTTTCTACCGCCTCAACG      
Forward   :  TTAGCAGACACGGACACAGG 
Podocin (NPHS2)       Reverse   :  CAGGAAGCAGATGTCCCAGT     
                      Forward   :  TGACGTTCCCTTTTTCCATC 
IL-6                   Reverse   :  CCAGAGGAAATTTTCAATAGGC 
Forward   :  TGATGCACTTGCAGAAAACA 
18s RNA               Reverse   :  AGGGCCTCACTAAACCATCC 
Forward   :  GCAATTATTCCCCATGAACG 
 
 
described. Nephrin mRNA quantification was performed assay on demand kits (Applied 
Biosystems, Warrington, UK)20,21,according to the manufacturer’s recommendations 
and Taq-Man RT-PCR was performed using a 7900HT Real Time PCR System 
(Taqman, Applied Biosystems) as previously described20,21. To accurately compare 
samples by means of real-time RT-PCR, identical number of cells (n=10000) were 
analyzed in all experiments and GAPDH was used to evaluate mRNA quality and 
integrity.  
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3.3 Methods part II 
 
3.3.1 Animal studies 
 
Male diabetic C57BLKS db/db mice 5-6 week old were obtained from Taconic 
(Ry, Denmark) and housed in filter top cages with a 12 h dark/light cycle. All animals 
had unlimited access to food and water throughout the study duration. At the age of 6 
weeks uninephrectomy (1K mice) was performed as described in “Methods part I”. All 
animal experiments were approved by the local government authorities. 
 
 
3.3.2 Cat S inhibitor R05461111 
 
RO5461111 (CAS 1252637-46-9) is a competitive inhibitor of the active site of 
Cat S. The nitril function of RO5461111 allows covalent reversible inhibition of Cat S. 
It was provided by F. Hoffmann-La Roche, Ltd., Basel, Switzerland. The synthesis and 
drug development of RO5461111 has been described in WO 2010121918.  
 
 
3.3.3 Study design 
 
At the age of 4 months, 1K db/db mice with documented blood glucose levels 
>11mmol/L and UACR >3 (ratio in age-matched wild-type mice = 0.1) were divided 
into two groups (n=10-12) and one group fed with food-drug mix contained 
RO5461111 (87.5 mg/kg, delivering a daily dose of 10 mg/kg body weight) and other 
group fed with standard food from 16 weeks of age till 24 weeks (Figure 11). Tissues 
were harvested for histopathological evaluation at the end of the treatment period. 
Blood and urine samples were obtained at monthly intervals. 
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Figure 11: Treatment protocol II 
 
 
3.3.4 RNA isolation, cDNA preparation and Real-time quantitative (RT-PCR) 
 
The detailed protocols for RNA isolation, cDNA preparation and RT-PCR were 
explained in “Method section, Part I”. In brief, total RNA from whole kidney was 
extracted using RNeasy mini extraction kit following the manufacturer’s instructions. 
1µg of RNA was transcribed into cDNA using Superscript II. The cDNA was further 
subjected to real-time PCR using the specific oligonucleotide primers (300 nM, 
Metabion, Martinsried, Germany) for the genes listed in Table 7. Quantitative detection 
of mRNA expression was performed using a Light Cycler 480, using SYBR green (SA 
Biosciences). The mRNA expression values for all genes were normalized to 18s rRNA 
in the respective cDNA preparations.  
 
 
 
 
 
 
↓↓↓ ↓↓↓
0          1             2             3                                                                                                      4                                             5                                                                 6 
Month of life 
 Vehicle- standard chow, ad libitum  
 RO5461111, food drug ad mix  
    (87.5 mg/kg food) 
 
Uninephrectomy at 6 week old 
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Table 7: Oligonucleotide primers used for SYBR-Green RT-PCR 
 
 
Target                Primer sequence 
 
Cat A                Forward  : AGAGCGGTCAGGCCAAGACG       
                Reverse  : CGCGGTTCCGGGCATCTCTG 
 
Cat B                Forward  : CTGCGCGGGTACTTAGGAGT 
                Reverse  : CAGGCAAGAAAGAAGGATCAAG 
 
Cat D                Forward  : TTCGTCCTCCTTCGCGATT       
                Reverse  : TCCGTCATAGTCCGACGGATA 
 
Cat K                Forward  : GCCAGGATGAAAGTTGTATG 
                Reverse  : CAGGCGTTGTTCTTATTCC 
 
Cat L                Forward  : GTGGACTGTTCTCACGCTCA 
                Reverse  : TATCCACGAACCCTGTGTCA 
   
Cat S                Forward  : AAGCGGTGTCTATGACGACCC 
                Reverse  : GAGTCCCATAGCCAACCACAAG 
 
IL6                    Forward  : TGATGCACTTGCAGAAAACA 
                       Reverse  : ACCAGAGGAAATTTTCAATAGGC 
 
TNF alpha              Forward  : AGGGTCTGGGCCATAGAACT 
                       Reverse  : CCACCACGCTCTTCTGTCTAC 
 
iNOS (NOS1)           Forward  : TTCTGTGCTGTCCCAGTGAG3, 
                       Reverse  : TGAAGAAAACCCCTTGTGCT 
 
eNOS (NOS3)           Forward  : TGGGCAACTTGAAGAGTGTGG 
                       Reverse  : AGAGTTCTGGGGGCTCATCA 
 
Ccl2                Forward  : CCTGCTGTTCACAGTTGCC 
                Reverse  : ATTGGGATCATCTTGCTGGT 
 
Nphs2 (Podocin)         Forward  : TGACGTTCCCTTTTTCCATC 
                       Reverse  : CAGGAAGCAGATGTCCCAGT 
 
Nphs1 (Nephrin)         Forward  : TTAGCAGACACGGACACAGG 
                       Reverse  : CTCTTTCTACCGCCTCAACG 
 
VCAM                 Forward  : CCGGCATATACGAGTGTGAA 
Reverse  : TCGGGCGAAAAATAGTCCTT 
 
ICAM                   Forward  : GTCACCGTTGTGATCCCTG 
Reverse  : AACAGTTCACCTGCACGGAC 
 
18s                    Forward  : GCAATTATTCCCCATGAACG 
                       Reverse  : AGGGCCTCACTAAACCATCC 
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3.3.5 FACS analysis of kidney cells 
Flow cytometric analysis of the whole kidney cell preparation was performed on 
a FACS Calibur flow cytometer from BD Biosciences. In brief, kidneys were 
mechanically disrupted and incubated in 1x Hanks´balanced salt solution (HBSS) 
containing 1 mg/mL collagenase type I and 0.1 mg/mL deoxyribonuclease type I for 20 
min at 37 °C. After washes, tissues were incubated in 5 ml 2 mmol/L EDTA in 1x 
HBSS for 20 min at 37°C. The supernatant containing isolated cells was kept on ice and 
the remaining pellet was incubated in 5 ml of 1 mg/mL collagenase-I in 1x HBSS for 20 
min at 37 °C. The suspension was subsequently passed through a 19-gauge, 27-gauge 
needle, and pooled with the first supernatant from the EDTA incubation. Cells were 
filtered through a 70-µm cell strainer and washed twice in PBS. All washing steps were 
performed in FACS buffer. The renal leukocytes were then characterized by using the 
following conjugated antibodies: PE anti-CD45, APC anti-CD11b, anti-Gr-1, FITC 
anti-Ly6C and anti-Ly6G.  
In cell culture stimulation experiments, the mouse glomerular endothelial cells 
(GENCs) were washed with PBS and incubated with binding buffer containing either 
FITC anti-Annexin V or PE propidium iodide. Apoptotic cells in the supernatants were 
washed, counted and analysed for the same surface markers mentioned above.  
 
 
 
3.3.6 Protein isolation and western blotting  
 
Protein isolation 
Proteins from kidney tissue were extracted using RIPA buffer (Sigma, Germany) 
containing protease inhibitors (Roche, Germany). In brief, part of the kidney tissue 
stored at -80 °C was homogenized using blade homogenizer for 30 seconds at 4 in RIPA 
buffer (500 µL) containing protease inhibitor. The lysates was then maintained at 
constant agitation for 2 h at 4 °C. The samples were then centrifuged for 20 min at 
12000 rpm at 4 °C. Then the supernatant (proteins) was separated into a new tube and 
the pallet was discarded. Protein estimation was done using Bradford’s assay.  
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Western blotting  
After determination of protein concentrations, 50 µg of the protein was mixed 
with 5x SDS loading buffer (100 mM Tris-HCl, 4% SDS, 20% glycerol, and 0.2% 
bromophenol blue) for Western blot analysis. Samples were heated at 95 °C for 5 min. 
Proteins were separated by SDS PAGE and then transferred to a poly-vinylidene 
difluoride (PVDF) membrane. Non-specific binding to the membrane was blocked for 1 
h at room temperature with 5% milk in Tris-buffered saline buffer (TBS, 20 mM Tris-
HCl, 150 mM NaCl, and 0.1% Tween 20). The membranes were then incubated 
overnight at 4 °C with primary antibodies. After washing, the membrane was incubated 
with respective secondary antibodies in TBS. The signals were visualized by an 
enhanced chemiluminescence system (Amersham, Buckinghamshire, UK). 
 
 
3.3.7 Invariant chain assay with mouse splenocytes 
 Mouse splenocytes were isolated by mechanical teasing of the whole spleen, 
followed by red blood cell depletion using Triton-X 100 lysis buffer for 30 min and 
centrifuged at 10,000g for 20 min to remove the cell debris. The supernatants were then 
loaded onto 10% SDS-PAGE; the proteins were then transferred onto nitrocellulose 
membrane and incubated with antibody against mouse CD74 antibody (BD 
biosciences), later incubated with anti-rabbit HP secondary antibody. The membrane 
was developed with ECL (GE Healthcare, Buckinghamshire, UK). 
 
 
3.3.8 In vitro studies 
All cells were cultured as previously described197. Murine immortalized 
podocytes were allowed to proliferate in RPMI 1640 medium (GIBCO/ Invitrogen, 
Paisley, Scotland, UK) containing 10% fetal calf serum, 100 U/ml penicillin, 100  
mg/mL streptomycin and 10 U/ml mouse IFN-γ (ImmunoTools, Firesoythe, Germany) 
at permissive temperature (33 °C), 5% CO2. Cells were differentiated at non-permissive 
conditions (37 °C), 5% CO2 without IFN-γ supplement for 10–14 days. For ECIS 
experiments, primary podocytes were isolated from mouse glomeruli as described 
elsewhere. All cells were cultured in RPMI 1640 GlutaMAXTM-I medium 
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supplemented with 10% FBS and 1% of penicillin and streptomycin. TECs were 
isolated and were grown to confluence in DMEM/F12 media containing 10% fetal calf 
serum, 1% penicillin–streptomycin, 125 ng/mL prostaglandin E1 (Calbiochem), 25 
ng/mL EGF (Sigma), 1.8 µg/mL L-thyroxine (Sigma), 3.38 ng/mL hydrocortisone and 
2.5  mg/mL of insulin-transferrin-sodium selenite supplement (I-TSS) (Sigma). All cells 
were stimulated with different concentration of glucose. HUVECs were stimulated with 
indicated growth factors and cytokines (R&D Systems) for 24 h. All cells were 
stimulated in serum free media. Cell-free supernatants were analysed for Cat S secretion 
by Luminex kit (in-house established).  
 
 
3.3.9 Electric cell impedance sensing assay (ECIS) 
 
Cat S induced changes in resistance and capacitance of all cells was analyzed 
using an ECIS device (Applied Biophysics Inc., NY, USA). Briefly, cells were re-
suspended in complete media and seeded in eight-well ECIS array plate containing 
small gold-film electrodes at a density of 100,000 cells/well in a volume of 400 µL 
media. Both the ECIS arrays and the measurement station were kept in an incubator 
with high humidity at 37 °C and 5% CO2. Cell attachment and confluency was 
monitored in terms of resistance/capacitance at every 30 sec for up to 24 h. Complete 
mono-layer covering the electrodes was confirmed microscopically prior to stimulation. 
All cells were then stimulated with different doses of Cat S with or without 
RO5461111. Capacitance was analyzed for indicated time points at 4000 Hz. All 
experiments were performed at least twice, every time in duplicates. 
 
 
3.3.10 In situ hybridization  
 In-situ hybridization was performed using Quantigene View RNA ISH Tissue 
Assay Kit (Affymetrix / Panomics Solutions). The assay uses proprietary chemistry for 
the target specific probe sets and branched-DNA signal amplification for detection of 
specific signal. Specific probe sets for mouse CTSS and F4/80 mRNAs were designed 
by Affymetrix based on the following sequences: NM_001267695 and NM_021281 for 
CTSS, NM_010130 for EMR1. Tissue sections of 4 µM prepared from Formalin Fixed 
Paraffin Embedded (FFPE) mouse kidney tissues were mounted onto micro slides (X-
Chemokines and Cysteine proteases in diabetic kidney disease                                                        Methods                                                                 
 
51 
 
tra TM Adhesive, Leica) and processed according to manufacturer instructions. Briefly, 
slides were baked for 1 h at 60 °C (Thermobrite, Abbott Molecular) and fixed in 10% 
formaldehyde for 1 h at RT. De-paraffinization was achieved using Histo-Clear reagent 
(National Diagnostics). Pre-hybridization conditions were found to be optimal with 10 
min of boiling at  95 °C and 10 min incubation at 40 °C with Protease QF diluted 
1/100x. Target probe set hybridization (Type-6 or Type-1 probe sets for blue or red 
staining respectively) was carried out for 2 h at 40 °C. Hybridized probes were 
amplified using PreAmplifier Mix QT and Amplifier Mix QT oligonucleotides 
incubating slides at 40 °C for 25 and 15 min respectively. Slides were then exposed to 
Label Probe conjugated with alkaline phosphatase (Label Probe 6-AP or 1-AP for blue 
or red staining respectively) for 15 min at 40 °C and to Fast Blue or Fast Red Substrates 
at RT for 15 min or at 40 °C for 30 min respectively. When 2-Plex assays were carried-
out, incubations with Label Probe 6-AP and Fast Blue Substrate were carried out before 
incubations with Label Probe 1-AP and Fast Red Substrate. Slides were counterstained 
with Gill’s Hematoxylin stain for 5-10 seconds at RT. After every incubation step, 
slides were washed 2-3 times in washing solution, PBS or water according to the 
manufacturer instructions. Imaging was performed under bright field with a Zeiss 
microscope equipped with an Axiocam MRC camera.  
 
 
3.3.11 In vivo microscopy on the mouse cremaster muscle 
The surgical procedure and the technical setup for in vivo microscopy on the 
mouse cremaster muscle have been previously described. For analysing post-ischemic 
leukocyte responses, the post-capillary vessel segments in a central area of the spread-
out cremaster muscle were randomly chosen among those that were at least 150 µm 
away from neighboring post-capillary venules and did not branch over a distance of at 
least 150 µm. After having obtained baseline recordings of leukocyte rolling, firm 
adhesion, and transmigration in all the vessel segments, ischemia was induced by 
clamping all supplying vessels at the basis of the cremaster muscle using a vascular 
clamp (Martin, Tuttlingen, Germany). Stagnancy of blood flow was then verified by in 
vivo microscopy. After 30 min of ischemia, the vascular clamp was removed and 
reperfusion was restored for 160 min. Measurements were repeated at 120 min after 
onset of reperfusion. For the quantitative analysis of the leukocyte migration 
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parameters, CapImage software (Dr. Zeintl, Heidelberg, Germany) was used. Rolling 
leukocytes were defined as those moving slower than the associated blood flow and 
quantified for 30 s. Firmly, adherent cells were determined as those resting in the 
associated blood flow for more than 30 s and related to the luminal surface per 100 µm 
vessel length. Transmigrated cells were counted in regions of interest (ROIs) covering 
75 µm on both sides of a vessel over 100 µm vessel length. For measurement of 
centerline blood flow velocity, green fluorescent microspheres (2 µm diameter; 
Molecular Probes, Leiden, The Netherlands) were injected via an arterial catheter and 
their passage through the vessels of interest were recorded. From measured vessel 
diameters and centerline blood flow velocity, apparent wall shear stress was calculated, 
assuming a parabolic flow velocity profile over the vessel cross section.  
As a measure of microvascular permeability, leakage of FITC dextran (Sigma 
Aldrich) into the perivascular tissue was analysed. After 130 min of reperfusion, FITC 
dextran was applied intra-arterially. Fluorescence in vivo microscopy measurements 
were performed 30 min later on five post-capillary vessel segments and the surrounding 
perivascular tissue. Mean gray values of fluorescence intensity were determined by 
digital image analysis (Image J) in six randomly selected ROIs (50x50 µm2), localized 
50 µm distant from the venule under investigation. Phenotyping of transmigrated 
leukocytes was performed on paraffin-embedded tissue sections immunostained with 
rat-anti-mouse CD45, Ly6G, or F4/80 mAb (Serotec, Oxford, UK) and counterstained 
with Mayer’s hemalaun. 
 
 
3.3.12 Human studies 
Human renal biopsies from patients and controls were collected within the 
framework of the European Renal cDNA Bank -Kroner-Fresenius Biopsy Bank (ref). 
Diagnostic renal biopsies were obtained from patients after informed written consent 
and with approval of the local ethics committees (Die Spezialisierte Unterkommission- 
SPUK fur Innere Medizin, University of Zurich). Total RNA was isolated from micro-
dissected samples taken from the tubulo-interstitial compartment. The fragmentation, 
hybridization, staining and imaging was performed according to the manufacturer’s 
guidelines (Affymetrix). For a detailed description and access to the deposited raw data 
of the protocol see reference (ref). A single probe-based analysis tool, ChipInspector 
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(Genomatix Software GmbH, Munich), was used for transcript annotation, total 
intensity normalization, significance analysis of microarrays and transcript 
identification based on significantly changed probes (ref). Real-time RT-PCR on 
biopsies from DN (n=12), and controls (living donors, LD, n= 9) was performed. 
Reverse transcription and real-time RT-PCR were performed as reported earlier (ref). 
Pre-developed TaqMan reagents were used for Cat S (CTSS, NM_004079) and the 
housekeeper gene GAPDH (Applied Biosystems). Data shown are normalized to 
GAPDH and target gene expression in the control cohort is set as 1. The mRNA 
expression was analysed by standard curve quantification. 
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4. Results  
 
4.1 Part I 
4.1.1 Plasma CCL2 and CXCL12 levels 
To assure Spiegelmer exposure and its biological activity in vivo, we determined 
plasma CCL2 and CXCL12 levels at the beginning and also at the end of the study. 
Anti-CXCL12 or anti-CCL2 Spiegelmer injections significantly increased the plasma 
levels of either chemokines in 1K db/db mice (Figure 11). Plasma CCL2 and CXCL12 
levels remained undetectable or low in sham-operated db/db mice and vehicle- or 
control Spiegelmer-treated 1K db/db mice. This is indicating that Spiegelmer 
antagonists retain their molecular targets in the circulation130,155,198.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Plasma chemokine levels in Spiegelmer-treated db/db mice. Plasma CCL2 and CXCL12 
levels were determined in 14 and 24 week old uninephrectomized db/db mice by ELISA which represent 
before and after treatment. Data are means ± SEM. *p<0.001 versus 24 week vehicle group.  
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4.1.2 Effect of dual blockade on body weight and blood glucose 
Treatment with CCL and CXCL12 dual blockade in uninephrectomized db/db 
mice did not show any significant changes in body weight and blood glucose levels 
compared to the vehicle-treated mice (Figure 12). This suggests that food admix did not 
influence the physiology of the treated mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Blood glucose levels and body weight in uninephrectomized db/db mice. (A) 
Uninephrectomized db/db mice with different treatments were monitored for blood glucose levels and (B) 
body weight from baseline at 16 weeks until the end of the study at 24 weeks of age. Data are means ± 
SEM. 
 
A 
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4.1.3  Dual CCL2/CXCL12 blockade has additive effects on glomerulosclerosis in 
db/db mice 
 
Renal histopathology  
Renal histomorphology in 6 months old db/db mice showed moderate 
glomerulosclerosis as compared to age-matched 2K non-diabetic mice which was 
aggravated to diffuse glomerulosclerosis by early uninephrectomy of db/db mice. CCL2 
as well as CXCL12 inhibition reduced the extent of glomerulosclerosis in 
uninephrectomized db/db mice to the level of age-matched sham-operated db/db mice 
while the control Spiegelmer had no effect (Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Renal pathology in 6 months old db/db mice.  Renal sections from 1K mice of the different 
treatment groups were stained with periodic acid Schiff (PAS). Stains show representative glomeruli from 
each group (original magnification 400x).   
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Glomerulosclerosis 
Dual CCL2/CXCL12 blockade improved glomerular pathology with 
significantly less severe lesions and more normal glomeruli as compared to either of the 
monotherapies. 1K db/db mice with dual blockade displayed even less glomerular 
pathology than age-matched 2K db/db mice (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: PAS stains from ‘Figure 13’ were scored for the extent of glomerulosclerosis from 0-4 as 
described. From each mouse 15 glomeruli from each renal section were graded by that score. The graph 
illustrates the mean percentage of each score ± SEM from all mice in each group. Uninephrectomy was 
associated with a shift towards higher scores of glomerulosclerosis as seen in the control Spiegelmer and 
vehicle-treated 1K db/db mice. Note that single blockade with either anti(α)-chemokine Spiegelmer 
significantly reduced the overall scores as compared to control Spiegelmer-treated 1K db/db mice (* 
p<0.05). Moreover, dual blockade further significantly reduced the percentage of glomeruli with a score 4 
and also increased the percentage of glomeruli with a score 1 as compared to either single chemokine 
blockade († p<0.05). 
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4.1.4 Dual CCL2/CXCL12 blockade improves the renal functional parameters and 
reduces proteinuria in db/db mice 
 
Glomerular function rate 
In CKD like DN, the decline in the GFR is associated with progression of the 
disease over a period due to loss of filtering ability. We therefore determined the GFR 
by assessing FITC inulin clearance kinetics in all groups of mice. Uninephrectomy was 
associated with a reduced GFR as compared to a normal GFR of about 350 mL/min in 
mice. Either CCL2 or CXCL12 blockade significantly increased GFR in 6 months old 
1K db/db mice (Figure 15). Dual CCL2/CXCL12 blockade was associated with the 
highest GFR compared to monotherapies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: GFR in 6 months old db/db mice. GFR was determined by FITC-inulin clearance kinetics in 
all groups at the end of the study as described in methods. Note that 1K db/db mice treated with dual 
chemokine blockade has higher GFR levels. Data are means± SEM from at least 6 mice in each group. * 
p<0.05, ** p<0.01 versus control-Spiegelmer treated 1K db/db mice. 
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Albumin/creatinine ratio (ACR) 
In DN, the progression of kidney disease is associated with increase in ACR, 
which is an important clinical parameter of glomerular dysfunction. We compared 
UACR at the beginning and at the end of the treatment course in all groups. CCL2 as 
well as CXCL12 blockade significantly reduced UACR when compared to control 
spiegelmer treatment at 6 months (Figure 16). When compared to baseline UACR, 
CXCL12 as well as dual blockade most effectively prevented proteinuria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Albuminuria in 6 months old db/db mice. UACR were determined as a functional marker 
of the glomerular filtration barrier at the initiation (4 months) and termination of treatment (6 months). 
Data are presented as means± SEM from at least 6 mice in each group. ** p<0.01, ***p<0.001 versus 
control-Spiegelmer treated 1K db/db mice in the respective group. 
 
 
 
4.1.5 Dual CCL2/CXCL12 blockade and glomerular cell counts in db/db mice 
Ki-67+ proliferating glomerular cells 
Glomerular pathology is often related to an altered cell turnover of glomerular 
cells, for example, mesangial cell proliferation and extracellular matrix accumulation. 
Therefore, we determined the total numbers of glomerular Ki-67+ proliferating 
glomerular cell. Total numbers of glomerular cells were determined by counting DAPI  
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Figure 17: Proliferation of glomerular cells in 1K db/db mice. Renal sections from mice of all groups 
were stained for the proliferation marker Ki-67 and the numbers of DAPI+ cell nuclei were counted in 
renal sections from mice of all groups as indicated. The graphs show the mean number of positive cells in 
15 glomeruli ± SEM in sections from 6 months old 1K db/db mice of each group.  
* p<0.05, ** p<0.01 versus control Spiegelmer treatment 
 
 
 
positive nuclei in glomerular tufts cross sections. None of the interventions significantly 
affect the total number of cell nuclei in glomerular tufts (Figure 17). The overall 
numbers of Ki-67+ proliferating cells within glomeruli were low but CCL2 and 
CXCL12 blockade both significantly reduced their numbers in glomeruli (Figure 17). 
 
 
 
4.1.6 CCL2 blockade reduces leukocyte numbers in glomeruli of 1K db/db mice 
 
Chemokine-mediated glomerular pathology in db/db mice can be mediated by 
leukocyte recruitment119,130. We therefore evaluated the number of glomerular 
leukocytes by immunostaining for CD45. Significant numbers of CD45 positive 
leukocytes were detected in glomeruli of vehicle or control Spiegelmer-treated 1K 
db/db mice (Figure 18). The numbers of glomerular CD45 positive leukocytes were 
significantly reduced by CCL2 but not by CXCL12 blockade130,155. The numbers of 
glomerular leukocytes were also reduced with dual chemokine blockade, accordingly 
(Figure 18).  
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                Vehicle                                               Anti-CCL2 
               Anti-CXCL12                    
         Anti-CCL2+anti-CXCL12                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Glomerular leukocyte infiltrates in 1K db/db mice. Renal sections from 1K mice of all 
treatment groups were stained for CD45 (original magnification 400x). The graph shows the mean 
number of CD45 positive cells in 15 glomeruli ± SEM in sections from 6 months old 1K db/db mice of 
each group. Note that only anti-CCL2 Spiegelmer affected the number of glomerular CD45+ cells (* 
p<0.01 versus control Spiegelmer, # versus both monotherapies).  
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4.1.7 Dual CCL2/CXCL12 blockade and renal mRNA expression of 
proinflammatroy and podocyte parameters in db/db mice 
 
We determined the mRNA expression levels of leukocyte- and podocyte-related 
genes in kidneys of 1K db/db mice. Both antagonists did not significantly alter 
intrarenal expression of their target gene (Figure 19). However, CCL2 blockade, and not 
CXCL12 blockade, was associated with lower mRNA levels of iNOS, a parameter of 
activated macrophages (Figure 19). The cytokine IL-6 showed a trend towards lower 
levels in all treatment groups. In contrast, CXCL12 blockade increased the mRNA 
levels of nephrin and podocin, two podocyte parameters, much more than CCL2 
blockade. Dual chemokine blockade increased these two podocyte markers most 
significantly (Figure 20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Renal mRNA expression in 1K db/db mice. RNA isolates from kidneys of 1K db/db mice 
underwent quantitative real-time PCR for a number of genes as indicated. Data are expressed as means of 
the ratio of the specific mRNA versus that of 18S rRNA ± SEM. * p<0.05, ** p<0.01, *** p<0.001 
versus vehicle). 
 Chemokines and Cysteine proteases in diabetic kidney disease                                                         Results 
 
 
63 
 
Podocin
Re
la
tiv
e 
ex
pr
es
s
io
n
/
18
s 
RN
A
Ve
hi
c
le
An
ti-
CX
CL
2
An
ti-
CC
L2
0
5.0×10-5
1.0×10-4
1.5×10-4
+
a
n
ti-
CX
CL
12
An
ti-
CC
L2
*
** ***
Nephrin
Re
la
tiv
e
 
ex
pr
e
s
si
o
n
/
18
s 
RN
A
Ve
hi
c
le
An
ti-
CX
CL
2
An
ti-
CC
L2
0
1.0×10 -4
2.0×10 -4
3.0×10 -4
4.0×10 -4
+
an
ti-
CX
CL
12
An
ti-
CC
L2
*
**
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Renal mRNA expression in 1K db/db mice. RNA isolates from kidneys of 1K db/db mice 
underwent quantitative real-time PCR for a number of genes as indicated. Data are expressed as means of 
the ratio of the specific mRNA versus that of 18S rRNA ± SEM. * p<0.05, ** p<0.01, *** p<0.001 
versus vehicle). 
 
 
4.1.8 Dual CCL2/CXCL12 blockade has additive effects on podocyte numbers in 
db/db mice 
 
We have previously documented that CXCL12 blockade protects 1K db/db mice 
from podocyte loss, as another marker of glomerular pathology in db/db mice155. We 
questioned whether dual chemokine blockade could have additive protective effects on 
podocytes. Thus, we quantified glomerular podocytes by WT-1 immunostaining in all 
groups of 1K db/db mice. Compared to an average number of 15-20 WT-1 positive 
podocytes in murine glomerular cross sections (data not shown) the 6 months old 1K 
db/db mice revealed only an average of 11 cells per glomerular cross section. CCL2 and 
particularly CXCL12 blockade both significantly increased glomerular podocyte counts 
(Figure 21). Interestingly, dual CCL2/CXCL12 blockade showed a small but 
statistically significant additive effect up to an average of 17 WT-1 positive cells per 
glomerular cross section (Figure 21).  
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Figure 21: Podocyte numbers in 1K db/db mice. Renal sections from 1K mice of all treatment groups 
were stained for WT-1 (original magnification 400x). The graph shows the mean number of WT-1 
positive cells in 15 glomeruli ± SEM in sections from 6 months old 1K db/db mice of each group. Note 
the potent effect of the anti-CXCL12 Spiegelmer on the number of podocytes (* p<0.05 versus control 
Spiegelmer) and the additive effect of dual blockade versus anti-CXCL12 monotherapy († p<0.05 versus 
both monotherapies).  
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4.1.9 CXCL12 suppresses nephrin de novo expression of podocyte progenitors  
 
How does CXCL12 blockade significantly increase podocyte numbers and 
nephrin expression without any direct effect on podocytes, which we had previously 
excluded?155 Given the critical role of CXCL12 in the maintenance of stem cell niches 
in multi-organ systems, we evaluated the possibility that podocyte-derived CXCL12 
may regulate the potential of renal progenitor cells to differentiate toward podocytes. 
Several groups have recently reported that a subpopulation of parietal epithelial cells 
(PECs) in glomeruli represent progenitor cells and have the capacity to differentiate into 
mature podocytes by progressively migrating and differentiating from the urinary pole 
of the Bowman’s capsule toward the glomerular tuft1557-19. We therefore questioned 
whether CXCL12 serves as a factor that regulates the differentiation of renal progenitor 
cells towards the podocyte phenotype. We indeed previously reported that155 culturing 
human renal progenitors in the VRAD medium over a period of 2 days resulted in their 
differentiation into podocytes, as demonstrated by novel expression of nephrin, WT-1, 
synaptopodin, podocin, PDX, and anti-glomerular epithelial protein 1 (GLEPP-1) at 
both mRNA and protein levels. Since in our in vivo models CXCL12 blockade 
upregulated nephrin expression, in this study we evaluated primary cultures of human 
renal progenitors, which are already known to express receptors for CXCL12155, for 
their potential to up regulate nephrin mRNA expression in presence or absence of this 
chemokine. The human embryonic kidney epithelial cell line 293 (HEK293) and human 
keratinocyte cell line (HACAT) were evaluated as additional controls for nephrin 
mRNA expression before and after treatment with VRAD. As shown in Figure 21A, the 
effect of VRAD treatment was irrelevant in HEK293 as well as in HACAT cell lines, 
while it induced a strong up-regulation of nephrin mRNA expression in primary 
cultures of human renal progenitors, as assessed by quantitative RT-PCR. Of note, 
adding recombinant CXCL12 suppressed nephrin mRNA up-regulation in a dose-
dependent manner (Figure 22A). When CXCL12 was blocked with anti-CXCL12 
spiegelmer, de novo mRNA expression of nephrin was no longer compromised, an 
effect that was not observed with the unspecific control spiegelmer (Figure 22B).  
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Figure 22: CXCL12 and de novo nephrin expression in renal progenitor cells. (A) HEK293, HACAT 
and human renal progenitors were cultured in VRAD medium as described in methods. Data are 
expressed as fold increase versus the respective untreated cell type, as assessed in identical number of 
cells. On human renal progenitors, recombinant CXCL12 was added at different concentrations as 
indicated and nephrin mRNA expression was determined by real-time RT-PCR. (B)  Cells were cultured 
as before plus adding anti-CXCL12 or control Spiegelmer. Note that only anti-CXCL12 Spiegelmer 
prevented the CXCL12-mediated suppression of de novo nephrin mRNA expression. Data are expressed 
as fold increase versus VRAD-treated renal progenitors (B), as assessed in identical number of cells. Data 
in A and B are means ± SEM. * p<0.05. 
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4.2 Results part II 
 
4.2.1 Cathepsin S expression in murine and human type 2 diabetic kidney disease  
     Cat S is associated with the pathophysiology of many inflammatory diseases and 
its inhibition by small antagonists was shown to be immunosuppressive in several 
mouse models. Previous studies with other cathepsin inhibitors suggested its protective 
role in diabetic kidney disease, but, so far, the role of Cat S in DN is unknown.  
     To study the role of Cat S in the progression of diabetic kidney disease, first we 
quantified the mRNA expression levels of cysteine Cat A, B, D, K, L and S in all solid 
organs of wild type BL6 mice. Gene expression profile revealed that Cat S is only found 
to be consistently expressed at much lower mRNA levels as compared to other Cats, 
especially in the kidney (Figure 23A). But, when the renal Cat S expression of 6 months 
old T2D male db/db mice was compared with their wild-type counterparts, a moderate 
induction was noted for Cats A, D, and S (Figure 23B). Interestingly, early 
uninephrectomy, which induces hyperfiltration as an accelerating patho-mechanism of 
glomerulosclerosis in T2D db/db mice, significantly induced Cat S selectively among 
all other studied Cats both at mRNA (Figure 24A) and protein level (Figure 24B) as 
compared to age matched controls.  
     Further, Cat S immunostaining on kidneys from 6 months old T2D male db/db 
mice displayed strong positivity in epithelial cells of proximal tubuli (Figure 25A). 
These cells, however, lacked any Cat S mRNA signal by in situ hybridization (Figure 
25B), implying that filtered Cat S protein gets passively reabsorbed from the glomerular 
filtrate but is not produced by TECs. In situ hybridization displayed Cat S mRNA 
positivity only in single cells within glomeruli and the tubulointerstitium that co-stain 
with the mononuclear phagocyte markers F4/80 and CD68 (Figure 25B).  
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Figure 23: Expression of CCs in kidneys of wild type and db/db mice. (A) mRNA expression pattern 
of CCs in all solid organs of wild type C57BL6 mice. (B) Differential mRNA expression levels of CCs in 
kidneys from 6 months old db/db- sham operated and uninephrectomized mice. Age matched WT mice 
served as a control. Data are expressed as means of the ratio of the specific mRNA versus that of 18S 
rRNA (n=5-12 mice in each group). * p<0.05 (db/db 1K versus Sham operated mice); #p<0.05 (WT 
versus Sham operated mice) 
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Figure 24: Expression of Cat S. (A) The relative expression of Cat S in kidneys of 6 weeks or 6 months 
old C57BL6 mice or db/db sham or uninephrectomized mice. (B) Western blot analysis of Cat S levels in 
kidneys extracts from 6 months old C57BL6 and db/db sham or uninephrectomized mice. Protein loading 
was corrected for sample protein concentrations and β-actin was used as a control. Data in A are 
expressed as means of the ratio of the specific mRNA versus that of 18S rRNA. Data in A and B are 
means ± SEM of 5-12 mice in each group. *p<0.05, **p<0.01, ***p<0.001age matched controls. 
 
 
To further explore the functional relevance of Cat S in human diabetic kidney 
disease, we performed both microarray and quantitative real time PCR analysis on 
micro-dissected kidney tissue samples received from an independent set of 4 and 5 
healthy and diseased individuals respectively. Both analysis revealed a 2-3 folds higher 
Cat S gene expression level at both glomerular and tubular compartments as compared 
to healthy kidney (Figure 26).   
      Thus, Cat S expression is selectively induced among other Cats in diabetic 
kidney disease, which originates to mononuclear macrophage infiltrates. In addition, 
tubular cells of the mouse kidney are loaded with Cat S protein even under 
physiological conditions, which suggests that circulating Cat S passes the GFB barrier 
and gets reabsorbed by proximal TECs. Together, these observations raise many 
possibilities for the potential role of Cat S in the pathogenesis of DN.  
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Figure 25: Cat S in-situ hybridization and immunohistochemistry. (A) Kidney sections were prepared 
for Cat S immunostaining and (B) for in-situ hybridization as described in methods. Cat S mRNA 
expression is indicated by red colour. Co-staining by either F4/80(macrophages), CD68 (myeloid DCs) is 
shown in blue colour, respectively. Representative images are shown here at original magnifications of 
100x, 200x. 
 
 
 
 
 
 
 
 
Figure 26: Cathepsin S gene expression in human DN: Microarray and real time PCR analysis were 
performed on micro-dissected glomeruli and tubulointerstitial compartments from human biopsies tissues 
of patients with DN ( n=5), and controls (living donar, LD, n=7). Gene expression of Cat S gene was 
significantly upregulated in DN, as compared to controls. Shown are the fold changes of the transcript 
with the highest probe coverage and quantitative Cat S mRNA expression by real-time RT-PCR. Shown 
are the fold changes of the expression. 
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4.2.2 RO5461111 inhibits Cat S activity in db/db mice 
To test the functional contribution of Cat S in diabetes, we used the inhibitor 
RO5461111 (Figure 27A). RO5461111 is a potent and highly selective compound that 
inhibits human Cat S with an IC50 of 0.4 nM and murine Cat S of 0.5 nM. No submicro-
molar inhibition of any other Cats (Cat B, Cat K, Cat L and Cat V) tested was detected 
(Table 8). Oral administration of RO5461111 by food admix (87.5 mg/kg of food) to 
male db/db mice resulted in a dose of 10 mg/kg body weight and resulted in robust 
lip10 (substrate for Cat S) fragment accumulation in spleens taken at 6 month of age 
(Figure 27B). RO5461111 bioactivity in vivo was also tested by measuring the plasma 
Cat S activity on Z-VVR-AFC substrate at the beginning and at the end of the study. 
RO5461111 treatment significantly suppressed the plasma Cat S activity as compared to 
vehicle-treated mice at 6 month of age and versus baseline activity at treatment 
initiation at 4 month of age (Figure 27C).  
Furthermore, RO5461111 treatment significantly down regulated the kidney Cat S 
expression at 6 months as evident by real time PCR and western blot (Figure 27D and 
27E). Together, RO5461111 is an orally available small molecule Cat S antagonist with 
favorable pharmacodynamic and pharmacokinetic profiles to efficiently block Cat S 
over a prolonged period of time in mice (with T2D). 
 
Table 8. In vitro enzyme inhibition assay 
Cathepsin IC50 
Human Cat S   0.4 nm 
Mouse Cat S   0.5 nm 
Human Cat K >25 µm 
Human Cat L   49 µm 
Human Cat B   44 µm 
Human Cat V   1.3 µm 
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Figure 27: RO5461111 selectively inhibits Cat S activity in db/db mice (A) Chemical structure of 
R05461111. (B) Invariant chain p10 levels were estimated from spleen tissue using western blotting. (C) 
The plasma Cat S activity was determined using Z-VVR-AFC substrate, before and after treatment at 6 
months old and baseline expression at 16weeks old db/db mice. (D) Renal mRNA expression levels of 
Cat-S in 1K db/db mice were determined by qPCR. (E) Western blot analysis of Cat S protein 
levels in kidney of 1K db/db mice. Data in D are expressed as mean±SEM of the ratio of the specific 
mRNA versus that of 18s ribosomal RNA. *p<0.05, **p<0.01, ***p<0.001 versus vehicle group (B, C 
and D) and #p<0.01 versus 16week old db/db mice (C) 
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4.2.3 RO5461111 treatment reduces glomerulosclerosis in db/db mice  
To test whether pharmacological blockade of Cat S with RO5461111 affects 
kidney disease in T2D, we fed uninephrectomized 1K db/db mice with either food 
admix that contained RO5461111 or standard diet. Treatment was continued for 8 
weeks from age 4 to 6 months, when kidneys were removed for analysis. RO5461111 
treatment significantly reduced the number of glomeruli affected by global 
glomerulosclerosis and increased the number of unaffected glomeruli as compared to 
mice fed with control diet (Figure 28A). Together, blockade of Cat S showed an overall 
improvement in the kidney pathology by reducing the glomerulosclerosis in 
uninephrectomized db/db mice (Figure 28B). 
 
 
4.2.4 RO5461111 treatment reduces podocyte loss in db/db mice 
Podocytes are an essential part of the GFB and podocyte injury and loss are the 
patho-mechanistic hallmark of proteinuria and glomerulosclerosis in diabetes26. So, we 
wondered whether RO5461111 treatment has any protective effect on podocytes loss in 
the glomeruli of uninephrectomized db/db mice. Therefore, we quantified WT-1 
positive cells in glomeruli of both treated and untreated 1K db/db mice at 6 month of 
age. RO5461111 treatment significantly increased the total numbers of glomerular 
podocytes (Figure 29A and Figure 29B) and this was associated with a significant 
increase in the renal mRNA expression levels of the podocyte slit diaphragm-related 
markers nephrin and podocin (Figure 29C). Together, therapeutic Cat S blockade with 
RO5461111 significantly prevented podocyte loss in uninephrectomized db/db mice. 
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Figure 28:RO5461111 reduces the glomerulosclerosis in 6 month old 1K db/db mice: (A) Renal 
pathology in 6 months old db/db mice: Kidney sections from both treated and untreated mice were stained 
with Periodic acid-Schiff (PAS) reagent. Stained images show representative glomeruli from each group 
(original magnification 400x). (B) PAS sections were scored to analyse the extent of glomerulosclerosis. 
15 glomeruli from one renal section were scored by using a semi-quantitative fashion ranging from 0-4 as 
described in the methods section. Note that uninephrectomy was associated with a shift toward higher 
scores of glomerulosclerosis as seen in vehicle treated mice, but with RO5461111 treatment the overall 
scores were significantly reduced. The graph illustrates the mean percentage of each score ± SEM from 
all mice in each group. Original magnification, 400x 
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Figure 29: Podocyte numbers in 1K db/db mice. (A) Renal sections from 1K mice of both treatment 
groups were stained for WT-1. Original magnification, 400x. (B) The graph shows the mean±SEM WT-1 
positive cells in 15 glomeruli in sections from 6month-old 1K db/db mice of both treated and untreated 
groups.  (C) Renal mRNA expression in 1K db/db mice. RNA isolates from kidneys of 1K db/db mice 
underwent quantitative real-time PCR for genes as indicated. Data are expressed as mean±SEM of the 
ratio of the specific mRNA versus that of 18s ribosomal RNA* p<0.05, ** p<0.01 versus vehicle group 
 
4.2.5 RO5461111 treatment reduces albuminuria in db/db mice 
Macroalbuminuria is a clinically important diagnostic and prognostic biomarker 
of glomerular injury in diabetes. So, we measured UACR at the end of the study in both 
treated and untreated animals. The beneficial effect of RO5461111 treatment on 
glomerulosclerosis and podocyte loss was associated with a 60% reduction of 
albuminuria as compared to the control diet-fed db/db mice (Figure 30).   
Together, Cat S blockade with RO5461111 significantly prevented podocyte 
loss, proteinuria, and glomerulosclerosis in T2D db/db mice. 
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Figure 30: Albuminuria in 6-month-old db/db mice. UACR were determined as a functional parameter of 
glomerular filtration at the end of the study. Data are given as the mean±SEM from at least eight mice in 
each group. ** p<0.01 versus vehicle group 
 
 
4.2.6 Cat S directly injures glomerular endothelial cells rather than podocytes  
To confirm the striking effect of Cat S inhibition on podocytes and to observe 
whether Cat S has direct effect on podocytes in vitro, we used the ECIS assay system 
which allows us to quantify monolayer barrier function by assessing trans-cellular 
electric capacitance (ref). Surprisingly, increasing doses of recombinant Cat S had no 
effect on  podocytes or other epithelial cell types (Figure 31A and 31B) while the trans-
cellular capacitance significantly increased in monolayers of GEnC (Figure 31C). This 
effect was reversible by RO5461111 co-incubation in a dose-dependent manner (Figure 
31C). How does Cat S affect endothelial barrier function? We found that Cat S exposure 
led to a dose-dependent-detachment of GEnC from culture dishes, a process that could 
be prevented by RO5461111 co-incubation (Figure 31D). In contrast, podocytes 
adherence remained unaffected by Cat S.  Together, Cat S does not directly impair 
barrier function or detachment of epithelial cells such as podocytes and TECs, but it 
leads to a dose-dependent detachment of endothelial cells. 
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Figure 31: Cat S impairs the endothelial barrier function in vitro: (A) Primary murine podocytes, (B) 
Tubular epithelial cells (TECs) and (C) GEnCs were cultured on ECIS culture ware and grown to 
confluency. Cells resistance and capacitance were analyzed for indicted time. Observe that Cat S had no 
effect on of podocytes or epithelial cell types (A and B), while the trans-cellular capacitance significantly 
increased in monolayers of GEnCs (C). This effect was reversible by RO5461111 co-incubation in a 
dose-dependent manner (C). (D) FACS analysis was done on floating GEnCs released into media after 
Cat S stimulation. Data in A and B are expressed as normalized resistance or capacitance ± SEM for three 
independent experiments. Data in C are represented as total cell number in millions. *p<0.05, **p<0.01 
versus control medium 
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4.2.7 RO5461111 reduces oxidative stress-induced vascular permeability in vivo 
Oxidative stress is a major element of endothelial dysfunction in diabetes that 
contributes to diabetes complications such as diabetic glomerulosclerosis. To test 
whether Cat S is a mediator of oxidative stress-related endothelial dysfunction, we 
performed M. cremaster in vivo microscopy upon local ischemia and monitored 
leukocyte recruitment and FITC-dextran leakage from the intravascular compartment 
into the interstitial space (as an in vivo model of endothelial activation and barrier 
dysfunction). RO5461111 treatment significantly reduced the trans- endothelial 
migration of leukocytes as well as the extravasation of dextran from the 
microvasculature (Figures 32A-C). In addition, studies have reported that mice lack in 
eNOS gene (endothelial nitric oxide synthase) developed the DN. To confirm the 
treatment effect on endothelial vasculature in db/db mice, we measured the mRNA 
expression levels of endothelial damage markers, VCAM, ICAM and eNOS in kidneys 
of both treated and untreated mice at 6 month old. R05461111 treatment significantly 
down regulated VCAM, but not ICAM as compared to vehicle fed mice (Figure 32D). 
Interestingly, eNOS expression was moderately upregulated in treatment group, 
indicating that R05461111 treatment restored the endothelial vasculature (Figure 32D). 
Thus, Cat S mediates oxidative-stress induced microvascular permeability. As 
proteinuria is a biomarker of endothelial dysfunction in diabetes, the Cat S-dependent 
albuminuria in db/db mice should relate to this phenomenon.  
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Figure 32: In vivo microscopy of cremaster muscles. In vivo microscopy was performed on cremaster 
muscle post-capillary venules as described in methods. (A) Leukocyte trans-endothelial migration was 
determined 130min after reperfusion. (B) Microvascular FITC-dextran leakage was determined 30min 
after dextran injection, i.e 130min after reperfusion. (C) Representative images illustrate the increase of 
vascular dextran permeability with (right) or without inhibitor (left image). (D) Renal mRNA expression 
of ED markers in 1K db/db mice. RNA isolates from kidneys of 1K db/db mice underwent quantitative 
real-time PCR for genes as indicated. Data are expressed as mean±SEM of the ratio of the specific 
mRNA versus that of 18s ribosomal RNA. Data in A B and D are means ± SEM.  # p< 0.05 versus 
vehicle. 
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4.2.8 Cat S blockade reduces glomerular leukocyte recruitment and inflammation 
in db/db mice with T2D 
 
Chemokine mediated leukocyte infiltrates play a key role in renal vascular 
inflammation in diabetes mellitus, and promote DN by local production of pro-
inflammatory mediators. Given the role of Cat S in leukocyte extravasation through 
activated endothelia, we speculated that Cat S would also promote glomerular leukocyte 
recruitment and glomerular inflammation. Flowcytometric analysis of renal cell 
suspensions prepared from uninephrectomized 1K db/db mice at the end of the study 
showed that RO5461111 treatment had significantly reduced intrarenal CD45+ 
leukocyte infiltrates, half of them each being neutrophils and Ly6C+ mononuclear 
phagocytes (Figure 33).  
 
 
 
 
 
 
 
 
 
 
 
Figure 33: FACS analysis of whole kidney cells for CD45 positive leukocytes, Ly6C and 7/4 double 
positive neutrophils and CD11b and Ly6C double positive macrophages. For each sample 50,000 events 
were counted.  Graphs represent the mean percentage of events for each group. Data represented are mean 
± SEM (n =5-7), * p<0.05, * p<0.001 versus vehicle treated group. 
 
 
Infiltrating glomerular macrophages are hallmark of renal vascular 
inflammation, and their accumulation is a characteristic feature of DN. We therefore 
evaluated the number of glomerular macrophages on kidney sections stained for Mac2 
(Figure 34A). Immunostaining revealed that RO5461111 treatment had significantly 
reduced the numbers of glomerular as well as interstitial macrophages compared to wild 
type and sham-operated db/db mice (Figure 34A and 34B).  
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Figure 34: (A) Renal sections from both treated and untreated mice were stained for Mac2. (original 
magnification x400). Values are shown as number of positive cells in 15 glomeruli. (B) The 
representative graphs show the number of Mac2 positive cells from each group. Note that all 
inflammatory leukocyte numbers were reduced in treatment group.  *** p<0.001 versus vehicle treated 
group, # p<0.01, db 2K vs vehicle 
 
 
We further determined the mRNA expression levels of proinflammatory and 
macrophage activation markers in kidneys of 6months old 1K db/db mice. In correlation 
with less macrophage number, RO5461111 treatment significantly reduced the renal 
mRNA expression levels of proinflammatory cytokines, IL-6 and TNF and macrophage 
related markers, iNOS and CCL2 (Figure 35).  
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Figure 35: Renal mRNA expression in 1K db/db mice. RNA isolates from kidneys of 1K db/db mice 
underwent quantitative real-time PCR for genes as indicated. Data are expressed as mean±SEM of the 
ratio of the specific mRNA versus that of 18s ribosomal RNA. * p<0.05 versus vehicle group 
 
Together, Cat S-driven endothelial dysfunction involves an increased 
microvascular permeability, which includes leukocyte transmigration and blockade of 
Cat S reduced renal leukocyte recruitment and inflammation in db/db mice with T2D. 
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5. Discussion 
 
5.1 Chemokine blockade in diabetic nephropathy 
 
DN is a leading cause of CKD16. It is well accepted that, inflammation plays a 
crucial role in promoting the development and progression of DN. Numerous 
pathomechanisms including increased local expression of growth factors and 
inflammatory mediators are known to induce DN20. The majority of chemokines 
belongs to the latter group of factors because pro-inflammatory chemokines promote 
tissue inflammation and remodelling by recruiting and activating immune cells in DN 
like in other types of kidney diseases50,52,199. For example, targeted deletion or inhibition 
of CCL2 and their receptor CCR2 prevented the glomerulosclerosis by blocking 
macrophage recruitment to glomeruli of mice with T1 and T2D118,119. Moreover, recent 
studies from our laboratory have shown that delayed onset of CCL2 blockade was able 
to prevent diabetic glomerulosclerosis by preventing glomerular macrophage 
recruitment in late-stage DN of uninephrectomized db/db mice with type 2 diabetes130.  
In addition, a subgroup of the chemokine super family, known as ‘homeostatic’ 
chemokines, displays functions independent of tissue inflammation76. For example, 
blockade of CXCL12 prevented diabetic glomerulosclerosis which was independent of 
glomerular macrophage recruitment, but a profound effect on podocyte counts and 
proteinuria was documented155. Therefore, we hypothesized that dual blockade of both 
chemokines; compared to monotherapies of either CCL2 or CXCL12 antagonists, might 
have beneficial effects in an accelerated mouse model of DN.  
Data of the present study confirm our previous reports on CCL2 blockade with 
Spiegelmers in the same experimental set up. In the present as well as in the previous 
studies CCL2 blockade resulted in a 50-60% reduction of glomerular leukocytes, which 
entirely represent macrophages in the db/db mouse model setup130. These findings are 
consistent with data from models of T1D and T2D in Ccl2-deficient mice or with CCR2 
blockade in 1K db/db mice118,119. CCR2+ macrophages belong to the proinflammatory 
(M1) phenotype that contribute to intrarenal inflammation and tissue damage via the 
release of ROS or cytokines like TNF-α. As such anti-CCL2-Spiegelmer-treated 1K 
db/db mice revealed lower numbers of glomerular leukocytes which were associated 
with lower intra-renal mRNA levels of iNOS, IL-6 or TNF-α at the end of the study. 
Consistent with our previous findings the protection from glomerulosclerosis with 
 Chemokines and Cysteine proteases in diabetic kidney disease                                                   Discussion 
 
 
 
84 
 
CCL2 blockade correlated with some lower levels of proteinuria and a higher GFR130. 
Thus, CCL2 blockade prevents the progression of DN by interfering with macrophage-
driven glomerular inflammation.  
The present study also reconfirms our previous data on CXCL12 blockade in 
this model155. It was interesting that NOX-A12 prevented the progression of 
glomerulosclerosis in 1K db/db mice without affecting glomerular leukocyte counts 
indicating that the homeostatic chemokine CXCL12 is not involved in glomerular 
leukocyte recruitment. We had recently reported that CXCL12 is rather constitutively 
expressed in podocytes155. CXCL12 blockade increased podocyte numbers in 1K db/db 
mice also in the present study. Furthermore, CXCL12 blockade increased the renal 
mRNA expression levels of nephrin and podocin, two podocyte slit membrane-related 
proteins that serve as markers of podocyte differentiation200. Podocyte damage is an 
important pathomechanism promoting the progression of diabetic glomerulosclerosis 
and seems to result from various triggers that foster podocyte dedifferentiation and 
podocyte apoptosis201.  
Till now, it remains unclear whether the beneficial effect of CXCL12 blockade 
on podocyte numbers relates to a protective effect on podocyte death or detachment or 
are rather due to enhanced podocyte regeneration from local podocyte progenitors, e.g. 
from PECs48,202. The latter concept may be more likely because, CXCL12 blockade also 
mobilizes hematopoietic progenitor cells from the bone marrow203-205. Moreover, in 
recent years, several studies have clearly demonstrated the existence of renal progenitor 
system (both glomerular and tubular) in the kidney48,202,206,207 (Figure 36). These studies 
have demonstrated that the renal progenitors which are localized between vascular and 
urinary pole express both progenitor and podocyte markers, which proliferate and 
differentiate to generate novel podocytes206. In addition, inhibition of Notch signalling 
enhanced  renal  progenitor  growth  and  increased  podocyte numbers  in  experimental  
models  of  FSGS47. By using in vivo multi-photon microscopy, Peterdi et.al. have 
demonstrated that, renal progenitors replaced the lost podocytes in rat models of PAN 
nephritis208. Consistent with these studies, our in vitro studies demonstrated that 
CXCL12 suppressed the induced maturation of renal progenitors towards podocytes as 
documented by inhibition of de novo nephrin expression. This effect was specific to 
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Figure 36: Representative diagram for kidney regeneration by different types of renal and 
extrarenal progenitors. CD24+CD133+ renal progenitors (red) are localized at the urinary pole and are 
in close contignuity with podocytes (green) at one extremity (the vascular stalk) and with tubular renal 
cells (yellow) at the other extremity. A transitional cell population (red/green) displays features of either 
renal progenitors (red) or podocytes (green) and localizes between the urinary pole and the vascular pole. 
At the vascular stalk of the glomerulus, the transitional cells are localized in close continuity with cells 
that lack progenitor markers, but exhibit the podocyte markers and the phenotypic features of 
differentiated podocytes (green). On the opposite side, at the urinary pole, transitional cells (red/yellow) 
with a mixed phenotype between tubular cells (yellow) and progenitor cells (red). The direction of 
differentiation is indicated by the arrows. Adapted from Romagnani et.al. 2013206 
 
renal progenitors and was not observed in other epithelial cells. Our in vitro finding that 
CXCL12 blockade reverts this inhibitory effect on nephrin expression may correspond 
to our in vivo observation where CXCL12 blockade increased renal nephrin mRNA 
expression and podocyte numbers. Thus, CXCL12 blockade may enhance renal 
progenitors differentiation toward the podocyte lineage, thus enhancing podocyte 
regeneration.  
One could thus hypothesize that dual blockade with anti-CCL2- and anti-
CXCL12-Spiegelmers could lead to Spiegelmer-Spiegelmer interaction effects like 
complex formation or additive off-target effects. However, the plasma chemokine level 
analysis confirmed that dual blockade does not significantly affect the biological 
activity of each Spiegelmer in terms of binding to its natural target (in the plasma). This 
observation is consistent with the finding that 1K db/db mice with dual blockade 
 Chemokines and Cysteine proteases in diabetic kidney disease                                                   Discussion 
 
 
 
86 
 
recapitulate the biological effects of single blockade. For example, 1K db/db mice 
treated with dual blockade displayed the reduction of glomerular leukocytes and a trend 
towards lower iNOS and TNF-α expression to the same extent as seen with CCL2 
blockade. In addition, dual blockade also increased podocyte numbers and nephrin or 
podocin mRNA expression to the same extent as seen with CXCL12 blockade only. As 
a result the combination of these blockades was more potent than single blockade in 
preventing diffuse glomerulosclerosis as evidenced by significantly less glomeruli with 
global glomerulosclerosis and significantly more normal glomeruli. This additive 
therapeutic effect was less prominent for GFR and proteinuria because CXCL12 
blockade by itself already had a profound effect on these two functional endpoints. 
Together, these data first document that chemokine antagonist combinations hold a 
potential for additive preventive effects on (diabetic) glomerulosclerosis when the 
individual chemokine targets mediate different pathomechanisms in the specific disease 
process, i.e. inflammation and renal progenitor differentiation toward the podocyte 
lineage. 
There are some limitations to the conclusions drawn from the present two studies.  
1. Based on previous studies in our laboratory, only a single dose of 
Spiegelmers (50 mg/kg body weight) was used.  But it might be possible 
that higher doses are even more effective. 
2. This study lacks supporting evidence from human experiments. However, 
Anti-CCL2 Spiegelmer (NOX-E36) is already in Phase IIa clinical trials to 
treat the diabetic kidney disease, whereas, NOX-A12 entered phase IIa 
clinical trials to treat multiple myeloma. (www.noxxon.com) 
 
 
5.2 Cathepsin S inhibition in diabetic nephropathy 
 
In this study, we have demonstrated that Cat S plays an important role in the 
progression of DN and inhibition of Cat S with R05461111 offers protection from the 
development of kidney disease in T2D. To the best of our knowledge, this is the first 
study that investigated the role of Cat S in the pathogenesis of DN.  
Patients with diabetes and atherosclerosis have higher Cat S plasma levels and 
the elastolytic properties of Cat S contribute to macro vascular complications and 
mortality184-186,209,210. However, the functional role of Cat S in microvascular diabetes 
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complications is not yet explored. We had hypothesized that Cat S contributes to kidney 
disease in T2D. Our studies confirm that Cat S localizes to the diabetic kidney and that 
Cat S inhibition with R05461111 reduces proteinuria, podocyte loss, and 
glomerulosclerosis in db/db mice. Additional in vitro and in vivo experiments suggest 
that Cat S contributes to endothelial dysfunction (ED), which is a central 
pathomechanism in microvascular complications of diabetes.  
Cat S mRNA expression in the healthy mouse kidney was low as determined by 
RT-PCR and in situ hybridization, but immunostaining revealed strong positivity, 
especially in tubules, which was consistent in mice and humans. This implies that 
circulating Cat S protein is filtered and passively reabsorbed in the renal tubules. 
However, advanced DN was associated with a significant increase in renal Cat S mRNA 
expression, which we could not properly localize by in-situ hybridization, most likely 
due to a lack of sensitivity of the method. Cat S immunostaining of mouse and human 
kidneys with advanced DN displayed increased positivity in all compartments and in 
vascular endothelial cells and infiltrating leukocytes, respectively. It is of note that 
therapeutic Cat S inhibition drastically reduced renal Cat S mRNA and protein 
expression, wherein the reduction in protein expression was much more pronounced, 
implying that the inhibition of systemic Cat S expression reduces the amount of renal 
deposition of Cat S protein. However, also the reduction of proteinuria may account for 
this effect.  
Cat S inhibition has a potent protective effect on proteinuria and podocyte loss 
and, to a lesser extent, on glomerulosclerosis. Podocyte loss is the central 
pathomechanism of DN progression as loss of podocytes cannot easily be replaced so 
that glomerular scaring progressively contributes to the loss of renal function19. We 
have identified Cat S-related biological effects that contribute to disease progression, 
i.e. ED and renal inflammation that were abrogated by therapeutic Cat S inhibition.  
ED has been implicated as a potential and central pathomechanism for both 
diabetic and non-diabetic renal vascular complications211.  As shown in figure 37, 
various factors of the diabetic milieu contribute to the development of ED which finally 
leads to DN. Microalbuminuria, a clinically important diagnostic and prognostic 
biomarker of glomerular injury, is now thought to be an early biomarker of ED, as 
increased vascular permeability leads to albumin leakage from the glomerular 
capillaries into the urine212 (Figure 38). In fact, micro-albuminuria is not always a 
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predictor of progressive DN but rather of cardiovascular complications in diabetes as 
well as in the non-diabetic population213-216. ED involves several alterations of normal 
endothelial cell functions, including increased oxidative stress217.  
Our in vivo microscopy studies document that Cat S is a mediator of vascular 
permeability upon oxidative stress. Cat S inhibition significantly improved 
microvascular permeability of FITC-dextran, a finding that may explain the reduction of 
proteinuria with Cat S inhibition in T2D db/db mice. Our in vitro studies document that 
Cat S specifically and dose-dependently increases endothelial cell monolayer 
permeability by inducing endothelial cell detachment and death, an effect that was not 
found with podocytes or other epithelial cells. But Cat S toxicity on endothelial cells                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Factors that contribute to the development of endothelial dysfunction in patients with 
diabetes. Factors including reactive oxygen species, eNOS inactivation and advanced glycation end 
products contribute to a reduction in the levels of nitric oxide in the endothelium, which in turn leads to 
endothelial dysfunction. Abbreviation: eNOS, endothelial nitric oxide synthase. Adapted and modified 
from Nakagawa, T. et.al. 2010212 
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Figure 38: Schematic representation of the relative changes occurring at GFB. Various factors 
released during the early stages of diabetic glomerulopathy damages the endothelial fenestrations which 
increases the vascular permeability leading to albumin leakage. Adapted from Karalliedde J, et. al. 
2011211 
 
in vivo is less severe, probably due to the presence of protease inhibitors210,218. Vice 
versa, decreased levels of cystatin C are associated with progressive cardiovascular 
disease by increasing the vascular activity of cysteine proteases219. 
ED in DN is further associated with reduced eNOS expression217, which is now 
thought to be an important pathophysiological link between ED and the functional and 
histopathological alterations in DN212. In fact, db/db mice show impaired eNOS 
activation along the progression of DN and restoring eNOS activity reduced the 
albuminuria as a marker of improved ED220. Also Cat S inhibition increased renal eNOS 
expression, which was associated with less proteinuria and protection from 
glomerulosclerosis in T2D db/db mice. These findings suggest that circulating Cat S 
and potentially local production of Cat S contribute to ED in diabetes, which manifests 
as increased microvascular permeability (proteinuria) and progressive 
glomerulosclerosis, the latter, for example, being driven by less eNOS production. Cat S 
inhibition has the potential to reverse these pathomechanisms in T2D db/db mice. 
Finally, neo-angiogenesis is another consequence of ED that contributes to the 
microvascular complications of diabetes, which is driven by Cat S221. 
Tissue remodeling in DN is also driven by local inflammation involving 
intrarenal cytokine and chemokine production and the recruitment of pro-inflammatory 
and pro-fibrotic macrophages that amplify the inflammatory response and produce pro-
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fibrotic mediators, respectively212,222. ED supports this process by endothelial cell 
activation, luminal expression of adhesion molecules and chemokines that support 
macrophage recruitment50. Cat S has the potential to modulate this inflammatory 
component of vascular disease as activated macrophages produce Cat S and contribute 
to vascular remodeling in atherosclerosis and vascular inflammation169,186,189. In fact, 
our data are consistent with this concept, as Cat S inhibition reduced intrarenal 
expression of VCAM and ICAM as well as renal leukocyte recruitment and the 
expression of pro-inflammatory mediators such as IL-6, TNF-α, iNOS, and CCL2. The 
significant reduction of intrarenal Cat S protein expression correlated with the lower 
number of leukocytes in db/db mice treated with RO5461111, suggesting that 
infiltrating leukocytes are a major source of Cat S production inside the diabetic kidney. 
This would be consistent with the strong Cat S staining intensity in infiltrating 
leukocytes into the renal interstitium in patients with advanced DN, which were not 
seen to the same extent in the mouse model.  
Together, Cat S inhibition is protective on kidney disease in T2D db/db mice. 
Our data suggest that Cat S is a mediator of ED, which implies microvascular 
permeability and inflammation, both driving tissue remodeling, i.e. progressive 
glomerulosclerosis. We conclude that Cat S is a mediator also of microvascular diabetes 
complications, which adds onto its known pathogenic role in macro-vascular disease. 
This implies that Cat S inhibition, for example with RO5461111, could elicit protective 
effects on vascular complications in diabetes223. However, there are some limitations to 
the conclusions drawn from this study. 
1. Only a fixed dose of Cat S inhibitor R05461111 (10 mg/kg body weight) 
was used throughout the study. But it might be possible that higher doses 
are even more effective.  
2.  It might be possible that blockade of Cat S lead to different results in other 
disease models. However, clinical trials with other Cat S inhibitors were 
shown to be more effective and safe in patients with Rheumatoid Arthritis. 
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6. Summary and conclusion 
 
 
CCL2/MCP-1 and CXCL12/SDF-1 both contribute to glomerulosclerosis in type 
2 diabetic mice, yet through different mechanisms. CCL2 mediates macrophage-related 
inflammation while CXCL12 contributes to podocyte loss. Antagonism of CCL2 and its 
receptor CCR2 are currently under phase III clinical trials for the treatment of diabetic 
kidney disease, whereas CXCL12 inhibition was also shown to be protective in various 
mouse models including, T2D. Dual blockade was significantly more effective than 
monotherapies in preventing glomerulosclerosis. CCL2 blockade reduced glomerular 
leukocyte counts and renal iNOS or IL-6 mRNA expression. CXCL12 blockade rather 
maintained podocyte numbers and renal nephrin and podocin mRNA expression. 
Consistently, CXCL12 blockade suppressed nephrin mRNA up regulation in primary 
cultures of human renal progenitors induced to differentiate towards the podocyte 
lineage. All aforementioned parameters were significantly improved in the dual 
blockade group which also suppressed proteinuria and was associated with the highest 
levels of GFR. Blood glucose levels and body weight were identical in all treatment 
groups. Together, dual blockade of CCL2 and CXCL12 found to be superior compared 
to single blockade in preventing the progression of diabetic glomerulosclerosis because 
both approaches target different disease pathomechanisms, i.e. inflammation and 
progenitor differentiation towards the podocyte lineage. Thus, dual CCL2/CXCL12 
blockade could be a novel strategy to more efficiently prevent glomerulosclerosis in 
T2D.  
Cat S is an elastolytic cysteine protease, known to drive vascular wall 
degeneration, a process that is independently associated with progressive vascular 
disease and all-cause mortality in patients with chronic kidney disease. Previous studies 
have shown that Cat inhibition was protective in various animal models of kidney 
diseases. In addition, Cat S inhibition was evolved as a novel therapeutic target in 
inflammatory and vascular disorders, but the pathogenic role of Cat S in kidney 
remodelling and progression of DN is not explored. Treatment with the orally available 
specific Cat S antagonist RO5461111 from month 4-6 of age significantly reduced 
albuminuria, podocyte loss, and glomerulosclerosis in association with lower 
glomerular and tubulointerstitial macrophage infiltrates as well as pro-inflammatory 
cytokines. In addition R05461111 significantly lowered the mRNA expression of 
adhesion molecules, VCAM and ICAM and restored eNOS expression. In vitro studies 
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with glomerular endothelial cells have documented a toxic effect of Cat S on endothelial 
cells in terms of viability, detachment, and permeability. In vivo microscopy studies 
revealed that cathepsin S inhibition with RO5461111 improved oxidative stress-induced 
microvascular permeability. Together, Cat S is a circulating mediator of endothelial 
dysfunction driving albuminuria and progressive kidney disease in T2D and Cat S 
blockade with R05461111 could be a novel therapeutic strategy to prevent the 
progression of DN and diabetes associated complications.  
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7. Zusammenfassung und Fazit  
 
 
CCL2/MCP-1 und CXCL12/SDF-1 sind beide an der Entwicklung der 
Glomeruloskerose im Rahmen von Typ 2 Diabetis beteiligt, dies aber durch 
unterschiedliche Mechanismen. CCL2 mediiert durch Makrophagen vermittelte 
Entzündungen wohingegen CXCL12 zum Podozytenverlußt beiträgt. Die Antagonisten 
von CCL2 und seinem Rezeptor CCR2 befinden sich momentan in der  Phase III der 
Zulassung (klinische Studien) für diabetische Nierenerkrankungen, zudem wurde auch 
gezeigt, dass CXCL12 Inhibierung einen protektiven Effekt in verschieden 
Mausmodellen zeigt, inklusive T2D. Es zeigte sich, dass durch eine duale Blockade eine 
signifikante Verbesserung der Glomerulosklerose nachweisbar war. Die CCL2 
Blockade führte zu einer verminderten renalen Leukozyteninfiltraton und ebenso zu 
einer verringerten renalen Expression von iNOS sowie IL-6 mRNA. Blockade von 
CXCL12 führte zu einem geringern Schwund an Podozyten und renalem Nephrin sowie 
Podocin mRNA Expression. Alle genannten Parameter waren in der dualen Blockade 
signifikant verbessert, außerdem konnte eine verminderte Proteinurie und eine höhere 
glomeruläre Filtrationsrate nachgewiesen werden. Blutzuckerwerte zeigten keine 
Unterschiede in den verschiedenen Gruppen.  Zusammenfassend ergibt sich daraus 
folgendes: eine gekoppelte Blockade von CCL2 und CXCL12 ist einer Blockade der 
einzelnen Komponenten überlegen. Dies zeigt sich in der Prävention der Progression 
der diabetischen Glomerulosklerose. Eine duale Blockade von CCL2 und CXCL12 
könnte eine neue effizientere Therapie darstellen um bei Patienten mit einem T2D eine 
Glomerulosklerose zu verhindern. 
 Cathepsin S ist eine Cystein-Protease, die durch Proteolyse elastischer Fasern 
Gefäße degeneriert. Ein Prozess der mit dem Fortschreiten vaskulärer Erkrankungen in 
Verbindung gebracht wird, die auch begleitend bei chronischen Nierenerkrankungen 
auftritt. Studien bestätigen das Cathepsin Inhibition zu einer Verbesserung in 
Tiermodellen mit Nierenerkrankungen führt.  Zusätzlich wurde CatS als ein neuer 
therapeutischer Ansatzpunkt für entzündliche und vaskuläre Veränderungen bestätigt. 
Jedoch ist die Rolle von CatS im Bereich des „Nieren-remodelling“ und der Progression 
von diabetischer Nephropathie bisher nicht untersucht. Hierzu wurde ein spezifischer 
CatS Antagonist RO5461111 an Mäuse obiger Linie in einem Alter von vier bis sechs 
Monaten oral verabreicht. RO5461111 reduzierte signifikant die mRNA Expression des 
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Adhäsionsmoleküls VCAM und stellte die eNOS mRNA Expression wieder her.  In 
vitro Studien mit glomerulären Endothelzellen zeigten einen toxischen Effekt von CatS, 
der sich hinsichtlich der Funktionsfähigkeit, Ablösung und Durchlässigkeit der Zellen 
darstellte.  Mikroskopische in vivo Untersuchungen zeigten das eine CatS Inhibition mit 
RO546111 zu einer Verringerung des oxidativen Stresses führt und dadurch eine 
geringere microvaskuläre Permeabilität auftritt.  Das Resume aus dem obigen ist, dass 
CatS ein im Blut zirkulierender Mediator für endotheliale Dysfunktion ist. CatS 
vermittelt Albuminurie und fortschreitende Nierenpathologie in T2D. R0546111 könnte 
als Antagonist von CatS ein neues Therapeutikum darstellen um die Progression der 
diabetischen Nephropathie zu mindern und den durch T2D vermittelte Komplikationen 
zu behandeln. 
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9. Abbreviations 
 
ACE   angiotensin converting enzyme  
AGEs   advanced glycation end products 
Ang II   angiotensin II 
AT1R   angiotensin II type 1 receptor  
AT2R   angiotensin II type 2 receptor 
BM   basement membrane  
BSA   bovine serum albumin 
cDNA   complementary DNA 
Cat(s)   cathepsin(s) 
CCL   chemokine C-C motif ligand 
CCR   chemokine C-C motif receptor 
CXCL   chemokine C-X-C motif ligand  
CXCR   chemokine C-X-C motif receptor 
CX3CR    chemokine C-X3-C motif receptor 
CKD   chronic kidney disease  
CT   cycle threshold 
DARC duffy antigen receptor for chemokines 
ddH2O  double distilled water 
DEPC diethyl pyrocarbonate 
DM diabetes mellitus 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO dimethyl sulfoxide 
DN diabetic nephropathy 
et al. et al.ii = and others 
eNOS endothelial nitric oxide synthase 
ECM extracellular matrix 
ED endothelial dysfunction 
EDTA ethylenediamintetra-acetic acid 
ELISA Enzyme-Linked Immunosorbent Assay 
ESRD end-stage renal disease 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
FITC fluorescein iso-thiocyanate 
GBM glomerular basement membrane 
GEnC  glomerular endothelial cell line 
GFR  glomerular filtration rate 
GPCR  G protein-coupled receptor 
HE  hematoxylin-Eosin 
HIV  human immunodeficiency virus 
hpf  high-power-field 
h/hrs  hour/hours 
ICAM-1  intercellular adhesion molecule-1 
i.e.  id est = in other words 
IL  interleukin 
IL-8  interleukin-8  
IFN-γ  interferon-γ 
IP-10  interferon inducible protein-10  
kDa  kilo dalton 
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K/DOQI kidney disease outcomes quality initiative 
MCP monocyte chemoattractant protein  
min minute/min 
MIP macrophage inflammatory protein  
mL/min milliliter/minute 
M/MØ monocytes / macrophages 
mNOX-E36 anti-CCL2 Spiegelmer  
mNOX-A12 anti-CXCL12 Spiegelmer 
mRNA messenger ribonucleic acid 
NADPH nicotinamide adenine dinucleotide phosphate 
NF-κB nuclear factor-κB 
NO nitric oxide  
NOS nitric oxide synthase 
O.D. optical density 
PAS periodic acid Schiff  
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PKC protein kinase C 
RANTES   regulated on activation normal T cell expressed and secreted  
RAS   renin angiotensin system 
revNOX-A12   control Spiegelmer for NOX-A12 
RNA   ribonucleic acid 
RNase   ribonuclease 
ROS   reactive oxygen species 
RPM   revolutions per minute 
RPMI Medium   cell culture medium  
rRNA   ribosomal ribonucleic acid 
RT   room temperature 
RT-PCR   real-time reverse transcription-polymerase chain reaction 
s    second 
STZ   streptozotocin 
T1D   type 1 diabetes 
T2D   type 2 diabetes 
TECs   tubular epithelial cells 
TGF-β   transforming growth factor-β 
Th1   T helper cell type 1 
TNF-α   tumor necrosis factor-α 
TZDs   thiazolidinediones 
UACR   urinary albumin creatinine ratio 
UUO   unilateral urethral obstruction  
VCAM-1   vascular cell adhesion molecule-1 
VEGF   vascular endothelial growth factor 
vs   versus 
v/v   volume/volume 
WT   wild type 
WT-1   wilms tumor 1 
1K   1 kidney 
2K   2 kidneys
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10. Appendix  
 
 
FACS buffer 
  Sterile DPBS     500 mL 
  Sodium azide    500 mg ( 0.1%) 
  BSA            1 g (0.2%) 
 
10X HBSS (Hank’s Balanced Saline Solution) without Ca, Mg 
 For 1000 mL: 
 KCl                 4 g 
 KH2PO4            0.6 g 
 NaCl                80 g 
 Na2HPO4.2H2O   0.621 g 
 Dissolve in 1000 mL and autoclave. 
 
DNAse stock solution (1 mg/mL) 
 DNAse (type III) 15000 U/6 mg (Sigma D5025) 
To prepare 1 mg/mL solution, add 6 ml of 50% (w/v) Glycerol in 20 mM Tris-
HCl (pH 7.5), 1 mM MgCl2.  
 Can be kept at -20 °C
 
for several weeks. 
 Caution: Solution is stable only for 1 week at 4 °C. 
 
Collagenase / DNAse solution 
 1 mg/mL Collagenase, 0.1 mg/mL DNAse in 1X HBSS (with Ca, Mg) 
 For 10 mL: 
 Collagenase (type I) (Sigma C0130)  10 mg 
 1 mg/mL DNAse stock solution      1 mL 
 HBSS (with Ca, Mg)               9 mL 
 To be pre-heated in 37 °C water bath before use. 
 Caution: Prepare freshly every time (Stable only for few days) 
 
Citrate buffer 10X 
 110 mM Sodiumcitrate in ddH2O  
 Adjust pH 6.0 with 2 N NaOH 
 
PBS 
 2.74 M NaCl 
 54 mM KCl 
 30 mM KH2PO4 
 130 mM Na2HPO4 in ddH2O  
 Adjust to pH 7.5 with HCl
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